<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J. Med. Chem</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-id journal-id-type="coden">jmcmar</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><publisher><publisher-name>American Chemical
Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29630818</article-id><article-id pub-id-type="pmc">PMC6007963</article-id><article-id pub-id-type="doi">10.1021/acs.jmedchem.8b00138</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>An <sup>18</sup>F-Labeled Poly(ADP-ribose)
Polymerase Positron Emission Tomography Imaging Agent</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="ath1"><name><surname>Zmuda</surname><given-names>Filip</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Blair</surname><given-names>Adele</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Liuzzi</surname><given-names>Maria Clara</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff3a" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Malviya</surname><given-names>Gaurav</given-names></name><xref rid="aff4" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Chalmers</surname><given-names>Anthony J.</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Lewis</surname><given-names>David</given-names></name><xref rid="aff4" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Sutherland</surname><given-names>Andrew</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Pimlott</surname><given-names>Sally L.</given-names></name><xref rid="aff6" ref-type="aff">#</xref></contrib><aff id="aff1"><label>&#x02020;</label>WestCHEM,
School of Chemistry, <institution>University of Glasgow</institution>, The Joseph Black Building, Glasgow G12 8QQ, <country>U.K.</country></aff><aff id="aff2"><label>&#x02021;</label>Wolfson
Whol Cancer Research Centre, Institute of Cancer Sciences, <institution>University of Glasgow</institution>, Glasgow G61 1QH, <country>U.K.</country></aff><aff id="aff3a"><sup>&#x000a7;</sup>School of Medicine, College of Medical, Veterinary
and Life Sciences, <institution>University of Glasgow</institution>, Glasgow G12 8QQ, <country>U.K.</country></aff><aff id="aff4"><label>&#x022a5;</label><institution>Cancer
Research UK Beatson Institute</institution>, Glasgow G61 1BD, <country>U.K.</country></aff><aff id="aff6"><label>#</label>West
of Scotland
PET Centre, <institution>Greater Glasgow and Clyde NHS
Trust</institution>, Glasgow G12 0YN, <country>U.K.</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>E-mail: <email>filipzmuda@gmail.com</email>. Phone: <phone>+44-(0)1413304924</phone>.</corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>04</month><year>2018</year></pub-date><pub-date pub-type="ppub"><day>10</day><month>05</month><year>2018</year></pub-date><volume>61</volume><issue>9</issue><fpage>4103</fpage><lpage>4114</lpage><history><date date-type="received"><day>26</day><month>01</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 American Chemical
Society</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>American Chemical
Society</copyright-holder><license><license-p>This is an open access article published under a Creative Commons Attribution (CC-BY) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html">License</ext-link>, which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2018-00138p_0011" id="ab-tgr1"/></p><p>Poly(ADP-ribose) polymerase (PARP)
is involved in repair of DNA
breaks and is over-expressed in a wide variety of tumors, making PARP
an attractive biomarker for positron emission tomography (PET) and
single photon emission computed tomography imaging. Consequently,
over the past decade, there has been a drive to develop nuclear imaging
agents targeting PARP. Here, we report the discovery of a PET tracer
that is based on the potent PARP inhibitor olaparib (<bold>1</bold>). Our lead PET tracer candidate, [<sup>18</sup>F]<bold>20</bold>, was synthesized and evaluated as a potential PARP PET radiotracer
in mice bearing subcutaneous glioblastoma xenografts using ex vivo
biodistribution and PET&#x02013;magnetic resonance imaging techniques.
Results showed that [<sup>18</sup>F]<bold>20</bold> could be produced
in a good radioactivity yield and exhibited specific PARP binding
allowing visualization of tumors over-expressing PARP. [<sup>18</sup>F]<bold>20</bold> is therefore a potential candidate radiotracer
for in vivo PARP PET imaging.</p></abstract><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm8b00138</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm-2018-00138p</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Poly(ADP-ribose) polymerase-1
(PARP-1) is a nuclear protein that
exhibits a broad range of functions and is involved in transcription,
mitosis, apoptosis, and DNA damage repair.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref></sup> PARP
inhibition has been investigated as a therapeutic approach to treat
cancers by either synthetic lethality in which tumor cells deficient
in a type of DNA repair termed homologous recombination are sensitized
to PARP inhibition, or chemoradiosensitization, in which PARP inhibition
sensitizes tumor cells to conventional chemo- or radiotherapy. To
date, olaparib (Lynparza), niraparib (Zejula), and rucaparib (Rubraca)
are the only PARP inhibitors to receive approval for clinical use
in the United States or Europe.<sup><xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref4">4</xref></sup> Olaparib (<bold>1</bold>; <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>) was the
first agent in its class to receive such approval. In the European
Union, it is currently indicated for the treatment of BRCA-mutated
(homologous recombination deficient) ovarian, fallopian-tube, and
peritoneal cancers,<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> in which it has been
shown to increase progression-free<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> and
overall<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> survival. In the United States, <bold>1</bold> can also be used for treatment of BRCA-mutated metastatic
breast cancer<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> and as a maintenance therapy
for patients with platinum-sensitive recurrent epithelial ovarian,
fallopian-tube, or primary peritoneal cancer irrespective of BRCA
mutations.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> In both cases, <bold>1</bold> was once again shown to increase progression-free survival.<sup><xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref></sup></p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>PARP
inhibitor olaparib.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2018-00138p_0001" id="gr5" position="float"/></fig><p>Olaparib <bold>1</bold> is also being investigated as a radio-
and chemosensitizer for the treatment of solid cancers, including
gliomas. However, adding PARP inhibitors to cytotoxic chemotherapy
agents has been shown to exacerbate bone marrow toxicity in humans,
hindering the establishment of effective PARP inhibitor and chemotherapy
dosage regimens with acceptable safety profiles.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> In the case of brain tumors, matters are further complicated
as <bold>1</bold> suffers from poor blood&#x02013;brain barrier (BBB)
permeability, and delivery of the drug to the tumor is reliant on
BBB disruption.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> The degree of BBB disruption
in brain tumors is very variable;<sup><xref ref-type="bibr" rid="ref13">13</xref>&#x02212;<xref ref-type="bibr" rid="ref15">15</xref></sup> this could affect tumor
penetration by <bold>1</bold> and, hence, reduce the clinical effectiveness
of PARP inhibitor therapy. Furthermore, in vivo animal studies have
revealed that prolonged treatment with <bold>1</bold> can result in
increased tumor <italic>P</italic>-glycoprotein efflux transporter
expression and subsequent drug resistance.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup></p><p>The above-mentioned issues highlight the challenges that are
associated
with PARP inhibitor therapy in the context of synthetic lethality
as well as chemo- and radiosensitization. Nuclear imaging of an appropriately
radiolabeled PARP inhibitor could be used to overcome these challenges.
In combination with a suitable blockade study protocol, nuclear imaging
could indirectly establish the distribution and retention of PARP
inhibitors in tumors and normal tissues and subsequently identify
therapeutic dosage regimens for which the combination of PARP inhibitors
and cytotoxic agents exerts maximal tumor and minimal bone marrow
cytotoxicity. Furthermore, a radiolabeled PARP probe could be used
to indirectly ascertain the occupancy, retention, and target engagement
of <bold>1</bold> in brain tumor tissue. This type of approach has
been successfully applied in preclinical models of small-cell lung<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> and epithelial ovarian cancer.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> In a clinical setting, this could be used to identify patients
that are unlikely to respond to PARP inhibitor therapy due to weak
target engagement as a consequence of poor drug tumor uptake or resistance
caused by efflux transporter over-expression.</p><p>Previously, we
reported the synthesis and characterization of a
[<sup>123</sup>I]-labeled compound with potential for single-photon
emission computed tomography (SPECT) imaging of PARP.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Despite the established nature of the SPECT imaging modality,
the use of positron emission tomography (PET) is rapidly expanding
and, in many cases, has become the preferred nuclear imaging modality
in the clinic. This can be attributed to the superior spatial resolution,<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> quantification, and sensitivity<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> of PET compared to SPECT. It is, therefore, not surprising
that many of the current nuclear imaging agents for PARP were designed
with PET imaging in mind (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>).<sup><xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref23">23</xref></sup> Importantly, the rationale for
developing PARP PET imaging agents has been recently solidified by
[<sup>18</sup>F]<bold>4</bold>, which was shown to be capable of noninvasively
ascertaining PARP-1 expression in epithelial ovarian tumors in humans.<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref24">24</xref></sup></p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Published
examples of PARP PET radiotracers.<sup><xref ref-type="bibr" rid="ref22">22</xref>,<xref ref-type="bibr" rid="ref23">23</xref></sup></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2018-00138p_0002" id="gr6" position="float"/></fig><p>Here, we report the synthesis of a small library
of fluorinated
analogs of the clinical PARP inhibitor <bold>1</bold> with potential
for PARP PET imaging and the in vitro characterization of these compounds.
The lead analog <bold>20</bold> was synthesized in its radiofluorinated
version and evaluated as a potential PARP PET radiotracer in mice
bearing subcutaneous glioblastoma xenografts using ex vivo biodistribution
and PET&#x02013;magnetic resonance (MR) imaging techniques.</p></sec><sec id="sec2"><title>Results
and Discussion</title><sec id="sec2.1"><title>Chemistry and in Vitro Characterization</title><p>Due to poor
accessibility of the central ring fluorine atom of <bold>1</bold> for
radiolabeling,<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> focus was directed at
synthesizing analogs of <bold>1</bold> bearing distal fluorinated
moieties that were more likely to be amenable to radiofluorination
methods. Initially, six fluorinated PARP inhibitors (<bold>8</bold>&#x02013;<bold>13</bold>) containing the characteristic phthalazinone
scaffold were synthesized through amide or <italic>N</italic>-alkyl
coupling of commercially available benzoic carboxylic acids or benzyl
halides with piperazine <bold>7,</bold> the synthesis of which we
described previously<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). The structures of compounds <bold>8</bold>&#x02013;<bold>13</bold> were confirmed in part by nuclear
magnetic resonance (NMR) spectroscopic analysis, which showed that
the majority of these exist as a mixture of amide rotamers. The design
of these analogs was partly driven by previous reports,<sup><xref ref-type="bibr" rid="ref25">25</xref>&#x02212;<xref ref-type="bibr" rid="ref27">27</xref></sup> which have shown that structural modifications can be performed
in the cyclopropane bearing region of <bold>1</bold> without having
a marked effect on PARP inhibition. To confirm this, cell-free PARP-1
IC<sub>50</sub> assays were performed on compounds <bold>8</bold>&#x02013;<bold>13</bold>, and the results of these experiments were compared against
the cell-free IC<sub>50</sub> of <bold>1</bold> (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). Compared to <bold>1</bold>, all compounds showed improved PARP-1 potency except for compound <bold>13</bold>, which had an overlapping cell-free IC<sub>50</sub> 95%
confidence interval. Compounds <bold>8</bold>&#x02013;<bold>13</bold> were also evaluated for their lipophilic and plasma protein binding
properties, defined by log <italic>P</italic><sub>oct</sub> and percentage
plasma protein binding (%PPB) parameters (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). All six analogs exhibited greater log <italic>P</italic><sub>oct</sub> and %PPB values in comparison to <bold>1</bold>. This may be attributed to the addition of aromatic and methyl moieties,
which have the potential to increase lipophilicity and can, in turn,
result in an increased %PPB due to the hydrophobic nature of plasma
protein interactions.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> From the perspective
of nuclear imaging, radiotracers with high log <italic>P</italic><sub>oct</sub> (&#x0003e;3.0)<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> and %PPB (&#x0003e;95%)<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> values can be associated with poor passive diffusion
across biological membranes and vascular retention, which can in turn
result in a poor target to background signal ratio. The physiochemical
parameters of <bold>8</bold>&#x02013;<bold>12</bold> were all found
to be within the optimal range for radiotracer development. However,
following analysis of the established in vitro parameters and potential
radiochemical accessibility, compound <bold>8</bold> was identified
as an initial lead candidate for further advancement in this research
program. To establish the potency of <bold>8</bold> against PARP in
living cells, cellular IC<sub>50</sub> assays were performed using
primary (G7) and secondary (T98G) human glioblastoma cell lines (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>) and previously described
methodology.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Compound <bold>8</bold> exhibited
low nanomolar IC<sub>50</sub> values that were in line with those
observed for <bold>1</bold> in both cell lines, suggesting that <bold>8</bold> was able to effectively penetrate cellular membranes and
reach PARP localized within cellular nuclei.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Methods
Used to Generate Analogs <bold>8</bold>&#x02013;<bold>13</bold> from
the Penultimate Compound 7 as
well as the Cell-Free PARP-1 Inhibitory and Physiochemical Properties
of <bold>1</bold> and <bold>8</bold>&#x02013;<bold>13</bold></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2018-00138p_0008" id="fx1" position="float"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2018-00138p_0009" id="fx2" position="float"/><table-wrap-foot><fn id="t1fn1"><label>a</label><p>Cell-free IC<sub>50</sub> values
are based on three experiments.</p></fn><fn id="t1fn2"><label>b</label><p>Lipophilicity (log <italic>P</italic><sub>oct</sub>) was determined
using a C-18 reverse-phase HPLC column.</p></fn><fn id="t1fn3"><label>c</label><p>Percentage plasma protein binding
(%PPB) was determined using a human serum albumin coated HPLC column.
Reagents and conditions for reaction below the table title: (a) HBTU,
Et<sub>3</sub>N, DMF, room temperature (rt), 72 h; (b) HBTU, DIPEA,
CH<sub>2</sub>Cl<sub>2</sub>, rt, 24 h; (c) EDCl, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, rt then reflux, 24 h; (d) HBTU, DIPEA, DMF, 50 &#x000b0;C,
24 h; (e) DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 24 h.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Cellular PARP Inhibitory
Properties
of Compounds <bold>1</bold> and <bold>8</bold></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th colspan="2" align="center" char=".">cellular
IC<sub>50</sub> (95% CI), nM<xref rid="t2fn1" ref-type="table-fn">a</xref><hr/></th></tr><tr><th style="border:none;" align="center">compound</th><th style="border:none;" align="center" char=".">G7</th><th style="border:none;" align="center" char=".">T98G</th></tr></thead><tbody><tr><td style="border:none;" align="left"><bold>1</bold></td><td style="border:none;" align="char" char=".">1.6 (1.4&#x02013;1.8)</td><td style="border:none;" align="char" char=".">1.6 (1.4&#x02013;1.8)</td></tr><tr><td style="border:none;" align="left"><bold>8</bold></td><td style="border:none;" align="char" char=".">1.0 (0.9&#x02013;1.2)</td><td style="border:none;" align="char" char=".">0.8 (0.7&#x02013;0.9)</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Cellular IC<sub>50</sub> values
obtained using primary G7 and established T98G human glioblastoma
cell lines are based on two experiments.</p></fn></table-wrap-foot></table-wrap><p>To access the [<sup>18</sup>F]-radiofluorine analog
of <bold>8</bold>, standard aromatic nucleophilic substitution chemistry
was employed
using <italic>p</italic>-nitrobenzamide precursor <bold>14</bold>,
which was generated through amide coupling of <bold>7</bold> with
commercially available 4-nitrobenzoic acid (<xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>). However, optimization of the radiofluorination
step proved challenging (see the <xref rid="notes-1" ref-type="notes">Supporting Information</xref>), and the maximum radiochemical yield (based on high-performance
liquid chromatography [HPLC] analysis of crude product) achieved was
only 19% (<xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>).
It was proposed that the poor yield was a consequence of a lack of
activation of the system for aromatic nucleophilic substitution due
to the weak electron withdrawing properties of the amide located <italic>para</italic>- to the nitro leaving group. Since commencing this
work, Carney et al. were able to synthesize [<sup>18</sup>F]<bold>8</bold> with an optimized radioactivity yield of 38 &#x000b1; 2.5%
(isolated product) using a multistep early-stage radiofluorination
approach that circumvented the aforementioned issue of poor activation.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> Therefore, our attention was redirected toward
an alternative target compound, <bold>20</bold>, bearing a <italic>p</italic>-(fluoromethyl)benzamide group. It was proposed that a
precursor analog of <bold>20</bold> would be more amenable to radiofluorination
than <italic>p</italic>-nitrobenzamide <bold>14</bold>, thereby allowing
for late-stage radiofluorination and radiosynthetic automation. Compound <bold>20</bold> was synthesized by first performing an amide coupling reaction
between mono-Boc protected piperazine <bold>15</bold> and commercially
available 4-(chloromethyl)benzoic acid, giving access to intermediate <bold>16</bold> in 40% yield (<xref rid="sch2" ref-type="scheme">Scheme <xref rid="sch2" ref-type="scheme">2</xref></xref>). <italic>p</italic>-Chlorobenzamide <bold>16</bold> was then subjected to nucleophilic fluorination with tetra-<italic>n-</italic>butylammonium fluoride (TBAF), and this was followed by
acid-mediated cleavage of the Boc-protecting group to give <bold>18</bold> in 87% yield over two steps. Finally, reaction of carboxylic acid <bold>19</bold>, previously synthesized within our research group,<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> and piperazine <bold>18</bold> under standard
amide coupling conditions gave target <bold>20</bold>. The log <italic>P</italic><sub>oct</sub>, %PPB, and cell-free and cellular IC<sub>50</sub> values were established for <bold>20</bold> in the same
manner as described for the other analogs (<bold>8</bold>&#x02013;<bold>13</bold>) in this series (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>).</p><fig id="sch1" position="float"><label>Scheme 1</label><caption><title>Radiofluorination Approach Used to Generate [<sup>18</sup>F]<bold>8</bold> From the Nitro Precursor <bold>14</bold></title><p id="s1fn1">Radiochemical
yield was determined
by radio-HPLC analysis of the crude product.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2018-00138p_0004" id="gr1" position="float"/></fig><fig id="sch2" position="float"><label>Scheme 2</label><caption><title>Synthetic Route Used to Generate Compound <bold>20</bold></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2018-00138p_0005" id="gr2" position="float"/></fig><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>Physiochemical, Cell-Free
PARP-1 and
Cellular PARP Inhibitory, and Mouse Plasma and Metabolic Stability
Properties of <bold>1</bold> and <bold>20</bold></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center" char=".">&#x000a0;</th><th style="border:none;" align="center" char=".">&#x000a0;</th><th style="border:none;" align="center" char=".">&#x000a0;</th><th colspan="2" align="center" char=".">cellular
IC<sub>50</sub> (95% CI), nM<xref rid="t3fn4" ref-type="table-fn">d</xref><hr/></th><th colspan="2" align="center" char=".">plasma
stability, percent<xref rid="t3fn5" ref-type="table-fn">e</xref><hr/></th><th colspan="2" align="center" char=".">Cl<sub>int</sub>, &#x003bc;L&#x000a0;min<sup>&#x02013;1</sup>mg<sup>&#x02013;1</sup><xref rid="t3fn6" ref-type="table-fn">f</xref><hr/></th></tr><tr><th style="border:none;" align="center">compound</th><th style="border:none;" align="center" char=".">log&#x000a0;<italic>P</italic><sub>oct</sub><xref rid="t3fn1" ref-type="table-fn">a</xref></th><th style="border:none;" align="center" char=".">%PPB<xref rid="t3fn2" ref-type="table-fn">b</xref></th><th style="border:none;" align="center" char=".">cell-free
IC<sub>50</sub> (95% CI), nM<xref rid="t3fn3" ref-type="table-fn">c</xref></th><th style="border:none;" align="center" char=".">G7</th><th style="border:none;" align="center" char=".">T98G</th><th style="border:none;" align="center" char=".">0 h</th><th style="border:none;" align="center" char=".">20 h</th><th style="border:none;" align="center" char=".">experiment
1</th><th style="border:none;" align="center" char=".">experiment
2</th></tr></thead><tbody><tr><td style="border:none;" align="left"><bold>1</bold></td><td style="border:none;" align="char" char=".">1.95</td><td style="border:none;" align="char" char=".">75.9</td><td style="border:none;" align="char" char=".">11.9 (10.5&#x02013;13.6)</td><td style="border:none;" align="char" char=".">1.6 (1.4&#x02013;1.8)</td><td style="border:none;" align="char" char=".">1.6 (1.4&#x02013;1.8)</td><td style="border:none;" align="char" char=".">&#x02013;</td><td style="border:none;" align="char" char=".">&#x02013;</td><td style="border:none;" align="char" char=".">23</td><td style="border:none;" align="char" char=".">34</td></tr><tr><td style="border:none;" align="left"><bold>20</bold></td><td style="border:none;" align="char" char=".">2.51</td><td style="border:none;" align="char" char=".">89.3</td><td style="border:none;" align="char" char=".">2.0 (1.9&#x02013;2.2)</td><td style="border:none;" align="char" char=".">1.3 (0.7&#x02013;2.3)</td><td style="border:none;" align="char" char=".">2.0 (1.3&#x02013;3.1)</td><td style="border:none;" align="char" char=".">93</td><td style="border:none;" align="char" char=".">95</td><td style="border:none;" align="char" char=".">74</td><td style="border:none;" align="char" char=".">90</td></tr></tbody></table><table-wrap-foot><fn id="t3fn1"><label>a</label><p>Lipophilicity (log <italic>P</italic><sub>oct</sub>) was determined using a C-18 reverse-phase HPLC column.</p></fn><fn id="t3fn2"><label>b</label><p>Percentage plasma protein binding
(%PPB) was determined using a human serum albumin coated HPLC column.</p></fn><fn id="t3fn3"><label>c</label><p>Cell-free IC<sub>50</sub> values
are based on three experiments.</p></fn><fn id="t3fn4"><label>d</label><p>Cellular IC<sub>50</sub> values
obtained using primary G7 and established T98G human glioblastoma
cell lines are based on two experiments.</p></fn><fn id="t3fn5"><label>e</label><p>The mean percentage of parent compound
remaining after a 20 h incubation in mouse plasma (&#x000b1;SD of 3 experiments)
was ascertained for compound <bold>20</bold>.</p></fn><fn id="t3fn6"><label>f</label><p>Intrinsic clearance (Cl<sub>int</sub>) values of
two independent experiments acquired using human liver
microsomes.</p></fn></table-wrap-foot></table-wrap><p>As expected,
compound <bold>20</bold> exhibited higher log <italic>P</italic><sub>oct</sub> and %PPB values
than <bold>1</bold> (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>). However, these were still within the optimal range for
a nuclear imaging agent. Interestingly, despite <bold>20</bold> having
an identical log <italic>P</italic><sub>oct</sub> value to <bold>8</bold>, the former compound exhibited a higher degree of %PPB. Furthermore,
compound <bold>20</bold> had a cell-free IC<sub>50</sub> value that
was 6- and 3-fold less than that acquired for <bold>1</bold> and <bold>8</bold>, respectively. Conversely, the cellular PARP inhibitory
properties of <bold>20</bold> were comparable to compound <bold>1</bold> and marginally weaker than ascertained for compound <bold>8</bold>. Collectively, the optimal physiochemical properties and low nanomolar
PARP cell-free and cellular IC<sub>50</sub> values supported further
investigation of <bold>20</bold> as a potential radiotracer for PARP.
In the body, radiotracers can be exposed to a number of metabolic
pathways, including blood plasma hydrolysis and liver functionalization
or conjugation reactions that can have a significant effect on the
kinetic properties of the tracer and, subsequently its usefulness
in nuclear imaging. With this in mind, the in vitro plasma and liver
microsome stability of lead candidate <bold>20</bold> were established
by incubating the compound in mouse plasma proteins and human liver
microsome enzymes, respectively, using previously described methodologies.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Candidate <bold>20</bold> appeared stable in
mouse plasma with negligible decomposition following a 20 h incubation
(<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>). However,
the intrinsic clearance parameter (a predictor of phase I liver metabolism)
was approximately 3-fold greater for compound <bold>20</bold> in comparison
to <bold>1</bold>. Despite this, it was proposed that compound <bold>20</bold> would exhibit sufficient tissue retention to allow for
nuclear imaging of PARP. This was justified by previously acquired
data using a radioiodinated <italic>p</italic>-iodobenzamide analog
that exhibited similar in vitro intrinsic clearance properties to <bold>20</bold> but still displayed a degree of retention in PARP over-expressing
tumor tissue.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup></p><p>Initial attempts
to generate the radiofluorinated version of <bold>20</bold> involved
performing nucleophilic substitution reactions
between the <sup>18</sup>F<sup>&#x02013;</sup> nucleophile and the
chloromethyl group of precursor <bold>21</bold>, which was obtained
by amide coupling of <bold>7</bold> with commercially available 4-(chloromethyl)benzoic
acid (<xref rid="sch3" ref-type="scheme">Scheme <xref rid="sch3" ref-type="scheme">3</xref></xref>). However,
these attempts were not successful because competing oligomerization
reactions between the chloromethyl group of <bold>21</bold> and the
phthalazinone core prevented effective radiofluorination. To overcome
this issue, the phthalazinone core of <bold>21</bold> was Boc-protected
to give compound <bold>22</bold>.</p><fig id="sch3" position="float"><label>Scheme 3</label><caption><title>Synthetic Route Used to Generate <italic>p</italic>-Chloromethylbenzamide
Precursor <bold>22</bold></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2018-00138p_0006" id="gr3" position="float"/></fig><p>Precursor <bold>22</bold> was then subjected to a screen
of radiofluorination
conditions as outlined in <xref rid="tbl4" ref-type="other">Table <xref rid="tbl4" ref-type="other">4</xref></xref>. The radiochemical yield (based on HPLC analysis of
the crude product) was 30% when tetra-<italic>n</italic>-butylammonium
hydrogen carbonate (TBAHCO<sub>3</sub>) was used as a phase-transfer
agent, which was markedly higher in comparison to that obtained for
Kryptofix (K<sub>222</sub>) (entries 1 and 2). It has been reported
in the literature that the introduction of a sterically hindered protic
alcohol can have a beneficial effect on aliphatic nucleophilic radiofluorination
reactions.<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> With the use of a 2:1 mixture
of <italic>t</italic>-BuOH and MeCN as the reaction solvent, the radiofluoride
incorporation increased from 30% to 48% in comparison to the same
volume of MeCN alone (entries 1 and 3). A 30 min reaction time was
established to be optimal based on lower radiochemical yields observed
after a shorter reaction time (entry 4) and the short-lived nature
of the <sup>18</sup>F radioisotope (half-life of 109.8 min), which
prevented longer reaction periods. Radiofluoride incorporation was
further improved by increasing the reaction temperature from 100 to
110 &#x000b0;C, which resulted in a 51% radiochemical yield (entry 5).
Interestingly, doubling the reaction solvent volume had a negative
impact on the degree of radiofluorination (entry 6). Based on these
data, the reaction conditions described in entry 5 were deemed optimal.</p><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><title>Optimization of the Nucleophilic Halogen
Exchange Methodology Used to Access Intermediate [<sup>18</sup>F]<bold>23</bold> from the Chloro Precursor <bold>22</bold></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2018-00138p_0010" id="fx3" position="float"/><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">entry</th><th style="border:none;" align="center">solvent (volume,
mL)</th><th style="border:none;" align="center">PTA<xref rid="t4fn1" ref-type="table-fn">a</xref></th><th style="border:none;" align="center" char=".">temperature, &#x000b0;C</th><th style="border:none;" align="center" char=".">reaction
time, min</th><th style="border:none;" align="center" char=".">radiochemical
yield, percent<xref rid="t4fn2" ref-type="table-fn">b</xref></th></tr></thead><tbody><tr><td style="border:none;" align="left">1</td><td style="border:none;" align="left">MeCN (0.3)</td><td style="border:none;" align="left">TBAHCO<sub>3</sub></td><td style="border:none;" align="char" char=".">100</td><td style="border:none;" align="char" char=".">30</td><td style="border:none;" align="char" char=".">30</td></tr><tr><td style="border:none;" align="left">2</td><td style="border:none;" align="left">MeCN (0.3)</td><td style="border:none;" align="left">K<sub>222</sub></td><td style="border:none;" align="char" char=".">100</td><td style="border:none;" align="char" char=".">30</td><td style="border:none;" align="char" char=".">4</td></tr><tr><td style="border:none;" align="left">3</td><td style="border:none;" align="left">MeCN (0.1)/ <italic>t</italic>BuOH (0.2)</td><td style="border:none;" align="left">TBAHCO<sub>3</sub></td><td style="border:none;" align="char" char=".">100</td><td style="border:none;" align="char" char=".">30</td><td style="border:none;" align="char" char=".">48</td></tr><tr><td style="border:none;" align="left">4</td><td style="border:none;" align="left">MeCN (0.1)/ <italic>t</italic>BuOH (0.2)</td><td style="border:none;" align="left">TBAHCO<sub>3</sub></td><td style="border:none;" align="char" char=".">100</td><td style="border:none;" align="char" char=".">10</td><td style="border:none;" align="char" char=".">22</td></tr><tr><td style="border:none;" align="left">5</td><td style="border:none;" align="left">MeCN (0.1)/ <italic>t</italic>BuOH (0.2)</td><td style="border:none;" align="left">TBAHCO<sub>3</sub></td><td style="border:none;" align="char" char=".">110</td><td style="border:none;" align="char" char=".">30</td><td style="border:none;" align="char" char=".">51</td></tr><tr><td style="border:none;" align="left">6</td><td style="border:none;" align="left">MeCN (0.2)/ <italic>t</italic>BuOH (0.4)</td><td style="border:none;" align="left">TBAHCO<sub>3</sub></td><td style="border:none;" align="char" char=".">110</td><td style="border:none;" align="char" char=".">30</td><td style="border:none;" align="char" char=".">37</td></tr></tbody></table><table-wrap-foot><fn id="t4fn1"><label>a</label><p>PTA: phase-transfer agent.</p></fn><fn id="t4fn2"><label>b</label><p>Radiochemical yields were determined
by radio-HPLC analysis of the crude product from a single reaction.</p></fn></table-wrap-foot></table-wrap><p>To access [<sup>18</sup>F]<bold>20</bold>, compound [<sup>18</sup>F]<bold>23</bold> was subjected
to Boc deprotection, which was achieved
in 5 min and with minimal defluorination taking place by using water
as an acid&#x02013;base catalyst (<xref rid="sch4" ref-type="scheme">Scheme <xref rid="sch4" ref-type="scheme">4</xref></xref>). The use of hydrochloric acid was also
investigated as a deprotecting agent, but its use was associated with
marked defluorination (see the <xref rid="notes-1" ref-type="notes">Supporting Information</xref>). The optimized two-step one-pot radiochemical reaction allowed
access to [<sup>18</sup>F]<bold>20</bold> in a radioactivity yield
(isolated product) of 9 &#x000b1; 2% (n = 7) and a molar activity of
&#x0003e;4.32 &#x000b1; 1.46 Ci &#x003bc;mol<sup>&#x02013;1</sup> (<italic>n</italic> = 3). Importantly, the one-pot nature of the reaction opens up the
potential for radiosynthetic automation.</p><fig id="sch4" position="float"><label>Scheme 4</label><caption><title>Optimized Radiofluorination
Approach Used to Generate [<sup>18</sup>F]<bold>20</bold></title><p id="s4fn1">Radioactivity
yield was determined
using the measured radioactivity of the isolated product.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2018-00138p_0007" id="gr4" position="float"/></fig></sec><sec id="sec2.2"><title>In Vivo Characterization</title><p>Following
successful optimization
of the radiochemistry, the behavior of [<sup>18</sup>F]<bold>20</bold> was investigated in vivo in mice bearing subcutaneous U87MG-Luc2
human glioblastoma tumor xenografts using ex vivo biodistribution
and PET&#x02013;MR imaging techniques. Ex vivo biodistribution of [<sup>18</sup>F]<bold>20</bold> was established at 30, 60, and 120 min
after intravenous radiotracer administration, and PET data were acquired
by performing a 45 min dynamic scan. These experiments showed that
a large proportion of radioactivity was detectable in the liver and
small bowel at 30&#x02013;45 min post tracer administration (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>a,b) and mostly concentrated
in the cecum matter and solid feces after 120 min (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>a). This is in line with our
previous findings<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> and other literature
reports,<sup><xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref34">34</xref></sup> which showed
in vivo hepatobiliary clearance of a range of related radioiodinated
and radiofluorinated compounds based on the structure of <bold>1</bold>. Interestingly, the mean percentage of injected dose per gram (%ID/g)
of femur tissue remained relatively high across all three biodistribution
time points (i.e., &#x0003e;8.5%; <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>a), which was also confirmed by PET imaging, in which
high skeletal uptake of radioactivity was visible (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>b). This is in contrast to
observations made by Carney et al., who reported &#x0003c;2%ID/g of bone
of [<sup>18</sup>F]<bold>8</bold> at 120 min.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> The high bone uptake seen with [<sup>18</sup>F]<bold>20</bold> could
be explained by in vivo defluorination and subsequent radiofluoride
accumulation in bone tissue.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> Despite
this, apparent radiotracer tumor uptake was identified in both biodistribution
and PET&#x02013;MR imaging experiments (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>a,c), whereas in the case of the former,
the mean ratio of %ID/g of glioblastoma tumor to muscle increased
from 1.9 &#x000b1; 0.5 (<italic>n</italic> = 4) to 3.6 &#x000b1; 0.5 (<italic>n</italic> = 4) between the 30 and 120 min time points. This was
suggestive of [<sup>18</sup>F]<bold>20</bold> retention in U87Mg-Luc2
glioblastoma tissue, which we have shown to be highly proliferative
(see the <xref rid="notes-1" ref-type="notes">Supporting Information</xref>) and to
over-express PARP relative to muscle tissue (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>d).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>(a) Ex vivo biodistribution of [<sup>18</sup>F]<bold>20</bold> in
subcutaneous human U87MG-Luc2 glioblastoma bearing nude mice 30 min
(<italic>n</italic> = 4), 60 min (<italic>n</italic> = 4), and 120
min (<italic>n</italic> = 4) after tracer injection (error bars represent
the mean percentage of injected dose per gram of tissue or material
(% ID/g) plus SD). (b) Mouse whole-body maximum intensity projection.
(c) 1T GRE 3D coronal and sagittal MRI, PET, and PET&#x02013;MR co-registered
images of a nude mouse bearing a subcutaneous U87MG-Luc2 human glioblastoma
(white arrows) acquired by performing a 45 min dynamic scan following
[<sup>18</sup>F]<bold>20</bold> administration (PET images represent
a summation of the last 15 min of the scan). (d) Representative immunohistochemistry
images of U87MG-Luc2 subcutaneous tumor and muscle tissue isolated
from nude mice stained for PARP-1 and counter-stained with hematoxylin
(brown staining signifies the presence of PARP-1, and dark blue staining
shows cellular nuclei). (e) Ratio of percentage of injected dose per
gram (%ID/g) of tissue of interest to muscle of [<sup>18</sup>F]<bold>20</bold>, 60 min after injection in subcutaneous U87MG-Luc2 human
glioblastoma bearing nude mice pretreated with either vehicle (<italic>n</italic> = 3) or 50 mg/kg of <bold>1</bold> (<italic>n</italic> = 3) (error bars represent the mean plus SD; unpaired <italic>t</italic>-test: <italic>P</italic> &#x0003c; 0.05).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm-2018-00138p_0003" id="gr7" position="float"/></fig><p>To establish the specificity of [<sup>18</sup>F]<bold>20</bold> for PARP in bone and tumor tissue, further biodistribution studies
were performed on subcutaneous U87MG-Luc2 glioblastoma bearing mice
that had PARP binding sites blocked by pretreatment with nonradioactive
compound <bold>1</bold> at a dose of 50 mg/kg 20 min prior to [<sup>18</sup>F]<bold>20</bold> administration. The uptake of [<sup>18</sup>F]<bold>20</bold> in bone tissue remained high 60 min after radioligand
administration and was not influenced by the presence of excess nonradioactive <bold>1</bold> (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>e). This supports the earlier proposed possibility of in vivo [<sup>18</sup>F]<bold>20</bold> defluorination, leading to free radiofluoride
accumulation in the bone. Despite this, preblockade using <bold>1</bold> resulted in a statistically significant decrease in the ratio of
%ID/g of tumor to muscle from 1.79 &#x000b1; 0.39 (<italic>n</italic> = 4) to 1.07 &#x000b1; 0.15 (<italic>n</italic> = 4) 60 min after [<sup>18</sup>F]<bold>20</bold> administration in comparison to vehicle-pretreated
mice (unpaired <italic>t</italic>-test: <italic>P</italic> &#x0003c; 0.05).
These findings suggested that the uptake of [<sup>18</sup>F]<bold>20</bold> in tumor was due to specific PARP binding, which was in
line with our previous findings for a related radioiodinated analog
of <bold>1</bold>.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup></p></sec></sec><sec id="sec3"><title>Conclusions</title><p>We described here the identification and one-pot manual radiosynthesis
of a PARP PET imaging agent, [<sup>18</sup>F]<bold>20</bold>, that
was accessed in good radioactivity yield and showed desirable physiochemical
properties but suffered from rapid hepatobiliary clearance and in
vivo defluorination followed by nonspecific <sup>18</sup>F<sup>&#x02013;</sup> bone tissue uptake in mice. Despite this, the radiotracer compound
exhibited specific PARP binding and subcutaneous glioblastoma tumor
retention properties, which allowed for preclinical PET visualization
of the PARP over-expressing tumor. Therefore, we believe that [<sup>18</sup>F]<bold>20</bold> should remain a potential candidate radiotracer
for in vivo PARP PET imaging and that future imaging studies using
small-animal intracranial glioblastoma models are required to further
assess the utility of this compound.</p></sec><sec id="sec4"><title>Experimental
Section</title><p>All reagents and starting materials were obtained
from commercial
sources and used as received. Dry solvents were purified using a solvent
purification system, and all reactions were performed under an atmosphere
of argon unless stated otherwise. Macherey-Nagel aluminum-backed plates
precoated with silica gel 60F<sub>254</sub> were used for thin layer
chromatography and were visualized with a UV lamp. Flash column chromatography
was performed using Fisher matrix silica gel 60 (35&#x02013;70 &#x003bc;m). <sup>1</sup>H NMR spectra were recorded on a Bruker DPX 400 or Bruker
500 spectrometer, and data are reported as follows: chemical shift
in parts per million (ppm) relative to Me<sub>4</sub>Si or the solvent
(CDCl<sub>3</sub>, &#x003b4; 7.26 ppm; CD<sub>3</sub>OD, &#x003b4; 3.31
ppm; or dimethyl sulfoxide [DMSO-&#x003b4;<sub>6</sub>] &#x003b4;, 2.50
ppm) as the internal standard, multiplicity (s, singlet; d, doublet;
t, triplet; q, quartet; m, multiplet or overlap of nonequivalent resonances,
integration). <sup>13</sup>C NMR spectra were recorded on a Bruker
DPX NMR spectrometer at either 101 or 126 MHz, and data are reported
as follows: chemical shift (ppm) relative to Me<sub>4</sub>Si or the
solvent as internal standard (CDCl<sub>3</sub>, &#x003b4; 77.2 ppm;
CD<sub>3</sub>OD, &#x003b4; 49.0 ppm; or DMSO-&#x003b4;<sub>6</sub>, &#x003b4;
39.5 ppm), multiplicity with respect to proton (deduced from DEPT
experiments; C, CH, CH<sub>2</sub>, or CH<sub>3</sub>). Infrared spectra
were recorded using a Shimadzu IRPrestige-21 spectrometer; wavenumbers
are indicated with units of cm<sup>&#x02013;1</sup>. Mass spectra were
recorded using electron impact, chemical ionization, or electrospray
techniques. High-resolution mass spectrometry (HRMS) results were
recorded using a JEOL JMS-700 spectrometer. Melting points are uncorrected.
All compounds used for biological testing exhibited &#x0003e;95% purity
as
per HPLC. Purity assessment of compounds <bold>8</bold>&#x02013;<bold>13</bold> was performed by injecting 0.5&#x02013;1.5 mg/mL of sample
of interest in 1:1 MeCN and 0.01 mM PBS (pH 7.4) onto a reverse-phase
Phenomenex Luna 5 &#x003bc;m C18 100 &#x000c5; (50 mm &#x000d7; 30 mm) column
under the following mobile-phase conditions: 0.0&#x02013;10.5 min,
100:0 to 10:90 A/B; 10.5&#x02013;11.5 min, 10:90 A/B; and 11.5&#x02013;12.0
min, 10:90 to 100:0 A/B, where A is PBS (pH 7.4) and B is MeCN. The
mobile-phase flow rate was 1.0 mL/min, and the column temperature
was set to 25 &#x000b0;C. Analytical UV detection was performed using
a UltiMate diode array detector (190&#x02013;800 nm). Purity assessment
for compound <bold>20</bold> was performed as described above using
the following mobile-phase conditions: 0.0&#x02013;15.0 min 70:30 to
5:95 A/B, where A is PBS (pH 7.4) and B is MeCN. Mice used for in
vivo studies were housed in individually ventilated cages and had
access to sterilized food and water ad libitum. All animal experiments
were carried out in compliance with UK Home Office regulations. The
synthesis of compounds <bold>1</bold>, <bold>7</bold>, and <bold>15</bold> has been reported previously.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup></p><sec id="sec4.1"><title>4-[3&#x02032;-[4&#x02033;-(4&#x02034;-Fluorobenzoyl)piperazine-1&#x02033;-carbonyl]-4&#x02032;-fluorobenzyl]-2<italic>H</italic>-phthalazin-1-one (<bold>8</bold>)</title><p>To a solution
of 4-fluorobenzoic acid (0.029 g, 0.21 mmol) in dichloromethane (5
mL) was added <italic>N</italic>,<italic>N</italic>-diisopropylethylamine
(DIPEA; 60.8 &#x003bc;L, 0.349 mmol) followed by 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU; 0.080 g, 0.21 mmol), and the mixture was
stirred vigorously under reflux for 1 h. Following this, <bold>7</bold> (0.064 g, 0.17 mmol) was added, and the mixture was stirred for
a further 24 h. On cooling to ambient temperature, water (5 mL) was
added and the organic layer washed with water (3 &#x000d7; 10 mL) and
a saturated NaHCO<sub>3</sub> solution (10 mL), dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo. Purification using
flash column chromatography (MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 3:97)
gave <bold>8</bold> (0.064 g, 75%) as a white solid; mp 166&#x02013;168
&#x000b0;C; IR (neat): 3202, 2922, 1629, 1425, 1285, 1223, 1152, 1005,
847 cm<sup>&#x02013;1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, &#x003b4;): 3.20&#x02013;4.05 (m, 8H), 4.29 (s, 2H), 6.98&#x02013;7.14
(m, 3H), 7.30&#x02013;7.45 (m, 4H), 7.68&#x02013;7.79 (m, 3H), 8.45&#x02013;8.49
(m, 1H), 11.37 (s, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>, &#x003b4;): 37.7 (CH<sub>2</sub>), 42.1 (2 &#x000d7; CH<sub>2</sub>),
47.0 (2 &#x000d7; CH<sub>2</sub>), 115.8 (2 &#x000d7; CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 21.9 Hz), 116.2 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 22.0 Hz), 123.6 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 17.8 Hz), 125.0 (CH),
127.2 (CH), 128.3 (C), 129.3 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.5 Hz), 129.5 (2 &#x000d7; CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C-F</sub> = 8.7 Hz), 131.1 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.5 Hz), 131.6 (CH), 131.8 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 8.0 Hz), 133.7 (CH), 134.5 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.5 Hz), 145.5 (C), 157.0 (C, d, <italic>J</italic><sub>C&#x02013;F</sub> = 247.4 Hz), 160.8 (2 &#x000d7; C), 163.6 (C, d, <italic>J</italic><sub>C&#x02013;F</sub> = 250.7 Hz), 165.2 (C), 169.7 (C); HRMS (ESI):
[MNa<sup>+</sup>] calcd for C<sub>27</sub>H<sub>22</sub>F<sub>2</sub>N<sub>4</sub>NaO<sub>3</sub>, 511.1552; found, 511.1547.</p></sec><sec id="sec4.2"><title>4-[3&#x02032;-[4&#x02033;-(2&#x02034;-Fluorobenzoyl)piperazine-1&#x02033;-carbonyl]-4&#x02032;-fluorobenzyl]-2<italic>H</italic>-phthalazin-1-one (<bold>9</bold>)</title><p>The reaction
was carried out as described for <bold>8</bold> using 2-fluorobenzoic
acid (0.047 g, 0.34 mmol), DIPEA (97.0 &#x003bc;L, 0.557 mmol), HBTU
(0.127 g, 0.334 mmol), and <bold>7</bold> (0.102 g, 0.278 mmol) in
dichloromethane (10 mL). Purification using flash column chromatography
(MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 3:97) gave <bold>9</bold> (0.072
g, 53%) as a white solid. NMR spectra showed a 56:44 mixture of rotamers.
Only the data for the major rotamer were recorded; mp 246&#x02013;248
&#x000b0;C; IR (neat): 3043, 2894, 1684, 1641, 1464, 1433, 1289, 1251,
1007, 775 749 cm<sup>&#x02013;1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) &#x003b4; 3.20&#x02013;4.10 (m, 8H), 4.30 (s, 2H),
6.96&#x02013;7.50 (m, 7H), 7.67&#x02013;7.81 (m, 3H), 8.42&#x02013;8.49
(m, 1H), 10.17 (br s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 101
MHz) &#x003b4; 37.7 (CH<sub>2</sub>), 41.8 (CH<sub>2</sub>), 42.2 (CH<sub>2</sub>), 46.8 (CH<sub>2</sub>), 47.4 (CH<sub>2</sub>), 115.9 (CH,
d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 21.4 Hz), 116.1
(CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 20.4 Hz),
123.4 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 17.8
Hz), 123.7 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 18.3 Hz), 125.0 (CH), 125.0 (2 &#x000d7; CH), 127.3 (CH), 128.4 (C),
129.3 (CH), 129.5 (C), 131.7 (CH), 131.8 (CH), 131.9 (CH), 133.7 (2
&#x000d7; CH), 134.4 (C), 145.5 (C), 157.1 (C, d, <italic>J</italic><sub>C&#x02013;F</sub> = 247.5 Hz), 158.1 (C, d, <italic>J</italic><sub>C&#x02013;F</sub> = 247.8 Hz), 160.1 (C), 165.2 (C), 165.5 (C); HRMS
(ESI): [MNa<sup>+</sup>] calcd for C<sub>27</sub>H<sub>22</sub>F<sub>2</sub>N<sub>4</sub>NaO<sub>3</sub>, 511.1552; found, 511.1545.</p></sec><sec id="sec4.3"><title>4-[3&#x02032;-[4&#x02033;-(4&#x02034;-Fluoro-2&#x02034;-methylbenzoyl)piperazine-1&#x02033;-carbonyl]-4&#x02032;-fluorobenzyl]-2<italic>H</italic>-phthalazin-1-one (<bold>10</bold>)</title><p>To a solution
of 4-fluoro-2-methylbenzoic acid (0.042 g, 0.27 mmol) in dichloromethane
(5 mL) was added EDCI (0.052 g, 0.27 mmol), and the reaction mixture
was stirred at ambient temperature for 0.5 h. 4-Dimethylaminopyridine
(DMAP; 0.017 g, 0.14 mmol) was then added and the mixture was stirred
for a further 0.5 h. A solution of <bold>7</bold> (0.100 g, 0.273
mmol) in dichloromethane (5 mL) was then added drop-wise and the resultant
reaction mixture stirred vigorously under reflux for 24 h. Upon cooling
to ambient temperature, water (5 mL) was added and the organic layer
washed with water (3 &#x000d7; 5 mL) and a NaHCO<sub>3</sub> solution
(5 mL), dried with MgSO<sub>4</sub>, filtered, and concentrated in
vacuo. Purification using flash column chromatography (MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 1:49) gave <bold>10</bold> (0.043 g, 31%)
as a white solid. NMR spectra showed a 59:41 mixture of rotamer. Only
data for the major rotamers were recorded; mp 175&#x02013;177 &#x000b0;C;
IR (neat): 3188, 2926, 1632, 1462, 1429, 1256, 1159, 1003, 772, 727
cm<sup>&#x02013;1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, &#x003b4;): 2.32 (s, 3H), 3.15&#x02013;3.45 (m, 4H), 3.55&#x02013;4.10
(m, 4H), 4.30 (s, 2H), 6.85&#x02013;7.18 (m, 4H), 7.26&#x02013;7.39
(m, 2H), 7.67&#x02013;7.81 (m, 3H), 8.43&#x02013;8.50 (m, 1H), 10.30
(s, 1H); <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>, &#x003b4;):
19.2 (CH<sub>3</sub>), 37.7 (CH<sub>2</sub>), 41.8 (CH<sub>2</sub>), 42.4 (CH<sub>2</sub>), 46.5 (CH<sub>2</sub>), 46.9 (CH<sub>2</sub>), 113.2 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 21.5 Hz), 116.3 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 20.6 Hz), 117.5 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 21.1 Hz), 123.6 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 17.0 Hz), 125.0 (CH), 127.2 (CH), 127.8 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C-F</sub> = 8.6 Hz), 128.3 (C), 129.3
(CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C-F</sub> =
3.2 Hz), 129.6 (C), 131.5 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;C&#x02013;F</sub> = 7.3 Hz), 131.6 (CH), 131.8 (CH), 133.7 (CH), 134.5 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.4
Hz), 137.4 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 8.1 Hz), 145.5 (C), 157.0 (C, d, J<sub>C&#x02013;F</sub> = 246.4
Hz), 160.7 (C), 162.9 (C, d, <italic>J</italic><sub>C&#x02013;F</sub> = 248.8 Hz), 165.3 (C), 169.6 (C); HRMS (ESI): [MNa<sup>+</sup>]
calcd for C<sub>28</sub>H<sub>24</sub>F<sub>2</sub>N<sub>4</sub>NaO<sub>3</sub>, 525.1709; found, 525.1696.</p></sec><sec id="sec4.4"><title>4-[3&#x02032;-[4&#x02033;-[(4&#x02034;-Fluorophenyl)acetyl]piperazine-1&#x02033;-carbonyl]-4&#x02032;-fluorobenzyl]-2<italic>H</italic>-phthalazin-1-one (<bold>11</bold>)</title><p>To a solution
of 4-fluorophenylacetic acid (0.043 g, 0.28 mmol) in dimethylformamide
(DMF; 5 mL) was added DIPEA (93.4 &#x003bc;L, 0.546 mmol) followed by
HBTU (0.105 g, 0.277 mmol), and the reaction mixture was stirred vigorously
at ambient temperature for 1 h. A solution of <bold>7</bold> (0.100
g, 0.273 mmol) in DMF (5 mL) was then added drop-wise, and the resultant
reaction mixture heated to and stirred at 50 &#x000b0;C for a further
24 h. The crude reaction mixture was worked up as described for as
described for <bold>8</bold>. Purification using flash column chromatography
(MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 1:24) gave <bold>11</bold> (0.063
g, 46%) as white solid. NMR spectra showed a 57:43 mixture of rotamers.
Only data for the major rotamer were recorded; mp 216&#x02013;218 &#x000b0;C;
IR (neat): 2899, 2346, 1636, 1586, 1508, 1431, 1219, 1157, 1011 cm<sup>&#x02013;1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, &#x003b4;):
3.03&#x02013;3.85 (m, 10H), 4.28 (br s, 2H), 6.95&#x02013;7.07 (m, 3H),
7.13&#x02013;7.24 (m, 2H), 7.27&#x02013;7.36 (m, 2H), 7.66&#x02013;7.79
(m, 3H), 8.44&#x02013;8.49 (m, 1H), 11.01 (s, 1H); <sup>13</sup>C NMR
(101 MHz, CDCl<sub>3</sub>, &#x003b4;): 37.7 (CH<sub>2</sub>), 39.9
(CH<sub>2</sub>), 42.0 (2 &#x000d7; CH<sub>2</sub>), 45.7 (CH<sub>2</sub>), 46.7 (CH<sub>2</sub>), 115.7 (2 &#x000d7; CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 21.4 Hz), 116.2 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 22.0 Hz), 123.5 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 17.6 Hz), 125.0 (CH),
127.2 (CH), 128.3 (C), 129.2 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C-F</sub> = 2.3 Hz), 129.5 (C), 130.2 (C), 130.2 (2 &#x000d7; CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C-F</sub> = 7.9 Hz), 131.6
(CH), 131.8 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C-F</sub> = 8.1 Hz), 133.7 (CH), 134.5 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;C-F</sub> = 3.4 Hz), 145.5 (C), 157.0 (C, d, <italic>J</italic><sub>C&#x02013;F</sub> = 247.6 Hz), 160.8 (C), 161.9 (C, d, <italic>J</italic><sub>C&#x02013;F</sub> = 247.6 Hz), 165.2 (C), 169.6 (C); HRMS (ESI): [MNa<sup>+</sup>]
calcd for C<sub>28</sub>H<sub>24</sub>F<sub>2</sub>N<sub>4</sub>NaO<sub>3</sub>, 525.1709; found, 525.1705.</p></sec><sec id="sec4.5"><title>4-[3&#x02032;-[4&#x02032;&#x02032;&#x02032;&#x02032;&#x02032;-[(4&#x02034;-Fluorophenyl)butane-1&#x02032;&#x02032;&#x02032;&#x02032;,4&#x02032;&#x02032;&#x02032;&#x02032;-dione]-piperazine-1&#x02034;-carbonyl]4&#x02033;-fluorobenzyl]-2<italic>H</italic>-phthalazin-1-one (<bold>12</bold>)</title><p>The reaction
was carried out as described for <bold>10</bold> using 3-(4-fluorobenzoyl)propionic
acid (0.053 g, 0.27 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDCI; 0.052 g, 0.27 mmol), DMAP, and <bold>7</bold> (0.100 g, 0.273
mmol) in dichloromethane (10 mL). Purification using flash column
chromatography (MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 1:24) gave <bold>12</bold> (0.050 g, 34%) as a pale yellow solid. NMR spectra showed
a 56:44 mixture of rotamers. Only data for the major rotamer were
recorded; mp 128&#x02013;130 &#x000b0;C; IR (neat): 3208, 2909, 1636,
1595, 1433, 1356, 1225, 1155, 1011 cm<sup>&#x02013;1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, &#x003b4;): 2.82 (t, <italic>J</italic> = 6.4 Hz, 2H), 3.24&#x02013;3.46 (m, 4H), 3.50&#x02013;3.98 (m, 6H),
4.28 (s, 2H), 7.05 (t, <italic>J</italic> = 8.8 Hz, 1H), 7.10&#x02013;7.16
(m, 2H), 7.30&#x02013;7.39 (m, 2H), 7.68&#x02013;7.81 (m, 3H), 8.00&#x02013;8.06
(m, 2H), 8.44&#x02013;8.49 (m, 1H), 10.33 (s, 1H); <sup>13</sup>C NMR
(101 MHz, CDCl<sub>3</sub>, &#x003b4;): 27.0 (CH<sub>2</sub>), 33.4
(CH<sub>2</sub>), 37.7 (CH<sub>2</sub>), 42.0 (CH<sub>2</sub>), 42.1
(CH<sub>2</sub>), 45.1 (CH<sub>2</sub>), 46.8 (CH<sub>2</sub>), 115.7
(2 &#x000d7; CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> =
21.8 Hz), 116.2 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 21.9 Hz), 123.7 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 17.6 Hz), 125.0 (CH), 127.2 (CH), 128.3 (C), 129.2 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.0 Hz), 129.6
(C), 130.8 (2 &#x000d7; CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 9.4 Hz), 131.6 (CH), 131.7 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 8.0 Hz), 133.2 (C), 133.6 (CH), 134.5 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.3 Hz), 145.5
(C), 157.0 (C, d, <italic>J</italic><sub>C&#x02013;F</sub> = 247.4
Hz), 160.7 (C), 165.3 (C), 165.8 (C, d, <italic>J</italic><sub>C&#x02013;F</sub> = 254.8 Hz), 170.5 (C), 197.4 (C); HRMS (ESI): [MNa<sup>+</sup>]
calcd for C<sub>30</sub>H<sub>26</sub>F<sub>2</sub>N<sub>4</sub>NaO<sub>4</sub>, 567.1814; found, 567.1796.</p></sec><sec id="sec4.6"><title>4-[3&#x02032;-[4&#x02033;-(4&#x02034;-Fluorobenzyl)piperazine-1&#x02033;-carbonyl]-4&#x02032;-fluorobenzyl]-2<italic>H</italic>-phthalazin-1-one (<bold>13</bold>)</title><p>To a stirred
solution of <bold>7</bold> (0.023 g, 0.063 mmol) in dichloromethane
(3 mL) was added 4-fluorobenzyl chloride (7.9 &#x003bc;L, 0.066 mmol)
followed by DIPEA (21.9 &#x003bc;L, 0.126 mmol). The resultant reaction
mixture was stirred at ambient temperature for 12 h, and then water
(5 mL) was added. The mixture was washed with water (2 &#x000d7; 5 mL)
and the organic layer was dried with MgSO<sub>4</sub>, filtered, and
concentrated in vacuo. Purification using flash column chromatography
(MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 1:9) gave <bold>13</bold> (0.011
g, 38%) as an off-white solid; mp 109&#x02013;111 &#x000b0;C; IR (neat):
3185, 2916, 1637, 1508, 1437, 1348, 1221, 1148, 999 cm<sup>&#x02013;1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, &#x003b4;): 2.34 (br
s, 2H), 2.50 (t, <italic>J</italic> = 5.2 Hz, 2H), 3.28 (br s, 2H),
3.48 (s, 2H), 3.75&#x02013;3.82 (m, 2H), 4.28 (s, 2H), 6.96&#x02013;7.04
(m, 3H), 7.24&#x02013;7.34 (m, 4H), 7.69&#x02013;7.78 (m, 3H), 8.44&#x02013;8.50
(m, 1H), 10.86 (s, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>, &#x003b4;): 37.8 (CH<sub>2</sub>), 42.0 (CH<sub>2</sub>), 47.1 (CH<sub>2</sub>), 52.5 (CH<sub>2</sub>), 53.0 (CH<sub>2</sub>), 62.0 (CH<sub>2</sub>), 115.2 (2 &#x000d7; CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 21.2 Hz), 116.1 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 21.8 Hz), 124.3 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 18.3 Hz), 125.1 (CH), 127.2 (CH), 128.3 (C), 129.1 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.8 Hz), 129.6
(C), 130.5 (2 &#x000d7; CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 7.9 Hz), 131.2 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 7.9 Hz), 131.6 (CH), 133.3 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.0 Hz), 133.7 (CH), 134.1 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.4 Hz), 145.6 (C), 157.0 (C, d, <italic>J</italic><sub>C&#x02013;F</sub> = 247.7 Hz), 160.5 (C), 162.1 (C, d, <italic>J</italic><sub>C&#x02013;F</sub> = 245.0 Hz), 164.8 (C); HRMS (ESI): [MH<sup>+</sup>] calcd for C<sub>27</sub>H<sub>25</sub>F<sub>2</sub>N<sub>4</sub>O<sub>2</sub>, 475.1940;
found, 475.1929.</p></sec><sec id="sec4.7"><title>4-[3&#x02032;-[4&#x02033;-(4&#x02034;-Nitrobenzoyl)piperazine-1&#x02033;-carbonyl]-4&#x02032;-fluorobenzyl]-2<italic>H</italic>-phthalazin-1-one (<bold>14</bold>)</title><p>To a solution
of 4-nitrobenzoic acid (92.0 mg, 0.550 mmol) in DMF (10 mL), was added
Et<sub>3</sub>N (119 &#x003bc;L, 0.880 mmol), followed by HBTU (231
mg, 0.610 mmol) and the mixture was stirred at room temperature for
1 h. Compound <bold>7</bold> (200 mg, 0.550 mmol) was added, and the
mixture was stirred at room temperature for a further 48 h. Water
(12 mL) was then added, followed by 1 h of stirring, after which the
mixture was cooled to 0 &#x000b0;C. The resulting precipitate was collected
by vacuum filtration, washed with water (4 &#x000d7; 20 mL), and dried
in vacuo to yield <bold>14</bold> (239 mg, 84%) as an orange foam.
NMR spectra showed a 3:2 mixture of rotamers. Only data for the major
rotamer were recorded; IR (neat): 3167, 3012, 2904, 1638, 1616, 1599,
1346, 1433, 1265, 1004, 735 cm<sup>&#x02013;1</sup>; <sup>1</sup>H
NMR (400 MHz, <italic>d</italic><sub>6</sub>-DMSO, &#x003b4;): 3.23
(s, 2H), 3.38 (s, 2H), 3.57&#x02013;3.86 (m, 4H), 4.39 (s, 2H), 7.21&#x02013;7.34
(m, 1H), 7.35&#x02013;7.53 (m, 2H), 7.69&#x02013;7.79 (m, 2H), 7.79&#x02013;8.05
(m, 3H), 8.25&#x02013;8.38 (m, 3H), 12.65 (s, 1H); <sup>13</sup>C NMR
(101 MHz, <italic>d</italic><sub>6</sub>-DMSO, &#x003b4;): 37.0 (CH<sub>2</sub>), 41.9 (2 &#x000d7; CH<sub>2</sub>), 46.9 (2 &#x000d7; CH<sub>2</sub>), 116.3 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 18.2 Hz), 123.8 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 18.0 Hz), 124.0 (2 &#x000d7; CH), 125.9 (CH), 126.5 (CH), 128.3 (C),
128.8 (2 &#x000d7; CH), 129.4 (CH), 129.5 (C), 132.0 (CH), 132.2 (CH,
d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 8.8
Hz), 133.9 (CH), 135.3 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.4 Hz), 142.3 (C), 145.2 (C), 148.4 (C), 156.8 (C d, <italic>J</italic><sub>C&#x02013;F</sub> = 245.7 Hz), 159.8 (C), 164.5 (C),
167.8 (C); HRMS (ESI): [MNa<sup>+</sup>] calcd for C<sub>27</sub>H<sub>22</sub>FN<sub>5</sub>NaO<sub>5</sub>, 538.1497; found, 538.1488.</p></sec><sec id="sec4.8"><title><italic>tert</italic>-Butyl Piperazine-4-[[(4&#x02032;-chloromethyl)benzoyl]-1&#x02032;carbonyl]-1-carboxylate
(<bold>16</bold>)</title><p>The reaction was carried out as described
for <bold>14</bold> using a solution of 4-(chloromethyl)benzoic acid
(183 mg, 1.07 mmol) in DMF (5 mL), Et<sub>3</sub>N (23.1 &#x003bc;L,
1.71 mmol), and HBTU (446 mg, 1.18 mmol). Compound <bold>15</bold> (200 mg, 1.07 mmol) was added, and the mixture was stirred for a
further 112 h. After this, water (10 mL) was added and the crude product
was extracted into dichloromethane (3 &#x000d7; 10 mL). The organic layers
were combined and washed with water (6 &#x000d7; 20 mL), dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to give a white solid.
Purification by flash column chromatography (hexane/EtOAc, 1:1) gave <bold>16</bold> as a white solid (144 mg, 40%); mp 140&#x02013;142 &#x000b0;C;
IR (neat): 3003, 2881, 1681, 1622, 1568, 1426, 1349, 1263, 1012, 724,
668 cm<sup>&#x02013;1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, &#x003b4;): 1.47 (s, 9H), 3.28&#x02013;3.84 (m, 8H), 4.60 (s, 2H),
7.43 (q, <italic>J</italic> = 11.9 Hz, 4H); <sup>13</sup>C NMR (101
MHz, CDCl<sub>3</sub>, &#x003b4;): 28.5 (3 &#x000d7; CH<sub>3</sub>), 43.8
(2 &#x000d7; CH<sub>2</sub>), 45.6 (CH<sub>2</sub>), 47.7 (2 &#x000d7; CH<sub>2</sub>), 80.5 (C), 127.6 (2 &#x000d7; CH), 128.8 (2 &#x000d7; CH), 135.6
(C), 139.4 (C), 154.6 (C), 170.1 (C); HRMS (ESI): [MNa<sup>+</sup>] calcd for C<sub>17</sub>H<sub>23</sub><sup>35</sup>Cl<sub>2</sub>N<sub>2</sub>NaO<sub>3</sub>, 361.1289; found, 361.1273.</p></sec><sec id="sec4.9"><title><italic>tert</italic>-Butyl Piperazine-4-[[(4&#x02032;-fluoromethyl)benzoyl]-1&#x02032;carbonyl]-1-carboxylate
(<bold>17</bold>)</title><p>To a solution of <bold>16</bold> (55.0
mg, 0.162 mmol) in MeCN (1.5 mL) was added a 1 M solution of TBAF
(325 &#x003bc;L, 0.325 mmol) in tetrahydrofuran. The mixture was heated
to 80 &#x000b0;C and stirred for 1 h followed by evaporation of solvent
in vacuo. The crude product was extracted into dichloromethane (5
mL), and the organic layer was washed with water (3 &#x000d7; 10 mL),
dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to
give <bold>17</bold> (52.0 mg, 100%) as a white solid; mp 96&#x02013;98
&#x000b0;C; IR (neat): 3013, 2928, 1690, 1630, 1420, 1250, 1009, 909,
756, 731 cm<sup>&#x02013;1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, &#x003b4;): 1.45 (s, 9H), 3.25&#x02013;3.84 (m, 8H), 5.40 (d, <italic>J</italic> = 47.4 Hz, 2H), 7.37&#x02013;7.43 (m, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>, &#x003b4;): 28.5 (3 &#x000d7; CH<sub>3</sub>), 42.2 (CH<sub>2</sub>), 43.7 (2 &#x000d7; CH<sub>2</sub>),
47.6 (CH<sub>2</sub>), 80.5 (C), 83.9 (CH<sub>2</sub>, d, <italic>J</italic><sub>C&#x02013;F</sub> = 167.6 Hz), 127.4 (2 &#x000d7; CH,
d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 6.2
Hz), 127.5 (2 &#x000d7; CH), 135.9 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;C&#x02013;C&#x02013;F</sub> = 2.6 Hz), 138.1 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 17.4 Hz), 154.6 (C), 170.2 (C); HRMS (ESI): [MNa<sup>+</sup>]
calcd for C<sub>17</sub>H<sub>23</sub>FN<sub>2</sub>NaO<sub>3</sub>, 345.1585; found, 345.1569.</p></sec><sec id="sec4.10"><title>Piperazine-4-[(4&#x02032;-fluoromethyl)benzoyl]-1&#x02032;carbonyl
(<bold>18</bold>)</title><p>To a solution of <bold>17</bold> (52.0
mg, 0.161 mmol) in dichloromethane (1 mL) was added trifluoroacetic
acid (124 &#x003bc;L, 1.61 mmol), and the mixture was stirred at room
temperature for 4 h. The crude product was extracted into EtOAc (5
mL), and the organic layer was washed using an aqueous saturated solution
of potassium carbonate (3 &#x000d7; 10 mL), dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to give <bold>18</bold> (31.0
mg, 87%) as an orange oil; IR (neat): 3411, 3001, 2957, 1613, 1437,
1276, 1263, 1016, 748 cm<sup>&#x02013;1</sup>; <sup>1</sup>H NMR (400
MHz, CDCl<sub>3</sub>, &#x003b4;): 2.80 (br s, 2H), 2.94 (br s, 2H),
3.38 (br s, 2H), 3.75 (br s, 2H), 5.40 (d, <italic>J</italic> = 47.5
Hz, 2H), 7.38&#x02013;7.45 (m, 4H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>, &#x003b4;): 43.3 (CH<sub>2</sub>), 46.0 (CH<sub>2</sub>),
46.5 (CH<sub>2</sub>), 49.0 (CH<sub>2</sub>), 84.0 (CH<sub>2</sub>, d, <italic>J</italic><sub>C&#x02013;F</sub> = 167.4 Hz), 127.3 (2
&#x000d7; CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 6.4 Hz), 127.4 (2 &#x000d7; CH), 136.3 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;C&#x02013;C&#x02013;F</sub> = 2.8 Hz), 137.7
(C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 17.4 Hz),
170.0 (C); HRMS (ESI): [MNa<sup>+</sup>] calcd for C<sub>12</sub>H<sub>15</sub>FN<sub>2</sub>NaO, 245.1061; found, 245.1064.</p></sec><sec id="sec4.11"><title>4-[3&#x02032;-[4&#x02033;-(4&#x02034;-Fluoromethyl)benzoyl)piperazine-1&#x02033;-carbonyl]-4&#x02032;-fluorobenzyl]-2<italic>H</italic>-phthalazin-1-one (<bold>20</bold>)</title><p>To a solution
of <bold>19</bold> (38.0 mg, 0.126 mmol) in DMF (1 mL) was added Et<sub>3</sub>N (26.0 &#x003bc;L, 0.189 mmol), followed by HBTU (52.6 mg,
0.139 mmol), and the mixture was stirred at room temperature for 1
h. Compound <bold>18</bold> (28.0 mg, 0.126 mmol) was added, and the
mixture was stirred for a further 72 h. Water (4 mL) was then added,
followed by 1 h of stirring, after which the mixture was cooled to
0 &#x000b0;C. The resulting precipitate was collected by vacuum filtration,
and the crude orange solid was purified by flash column chromatography
(MeOH/EtOAc, 1:19) gave <bold>20</bold> (10.7 mg, 17%) as a yellow
foam; IR (neat): 3213, 3005, 2926, 1613, 1572, 1429, 1256, 1225, 1003,
750 cm<sup>&#x02013;1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, &#x003b4;): 3.13&#x02013;4.02 (m, 8H), 4.29 (s, 2H), 5.41 (d, <italic>J</italic> = 47.3 Hz, 2H), 7.04 (br s, 1H), 7.34 (d, <italic>J</italic> = 6.2 Hz, 2H), 7.43 (br s, 4H), 7.67&#x02013;7.72 (m, 1H), 7.73&#x02013;7.80
(m, 2H), 8.44&#x02013;8.49 (m, 1H), 10.70 (br s, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>, &#x003b4;): 37.8 (CH<sub>2</sub>),
42.3 (2 &#x000d7; CH<sub>2</sub>), 47.2 (2 &#x000d7; CH<sub>2</sub>), 84.0
(CH<sub>2</sub>, d, <italic>J</italic><sub>C&#x02013;F</sub> = 167.8
Hz), 116.3 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 19.9 Hz), 123.8 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 18.2 Hz), 125.1 (CH), 127.4 (CH), 127.5 (2 &#x000d7; CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 6.0 Hz), 127.6
(2 &#x000d7; CH), 128.5 (C), 129.4 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.7 Hz), 129.7 (C), 131.8 (CH), 132.0 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 8.2 Hz), 133.8 (CH), 134.6
(C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.5 Hz), 135.5 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;C&#x02013;C&#x02013;F</sub> = 2.8 Hz), 138.5 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 17.5 Hz), 145.6 (C), 157.1 (C, d, <italic>J</italic><sub>C&#x02013;F</sub> = 247.1 Hz), 160.5 (C), 165.3 (C), 170.3 (C); HRMS (ESI): [MNa<sup>+</sup>] calcd for C<sub>28</sub>H<sub>24</sub>F<sub>2</sub>N<sub>4</sub>NaO<sub>3</sub>, 525.1714; found, 525.1738.</p></sec><sec id="sec4.12"><title>4-[3&#x02032;-[4&#x02033;-(4&#x02034;-Chloromethyl)benzoyl)piperazine-1&#x02033;-carbonyl]-4&#x02032;-fluorobenzyl]-2<italic>H</italic>-phthalazin-1-one (<bold>21</bold>)</title><p>The reaction
was carried out as described for <bold>14</bold> using a solution
of 4-(chloromethyl)benzoic acid (18.7 mg, 0.110 mmol) in DMF (1 mL),
Et<sub>3</sub>N (24.0 &#x003bc;L, 0.180 mmol) and HBTU (45.6 mg, 0.120
mmol). Following the addition of <bold>7</bold> (40.0 mg, 0.110 mmol)
the mixture was stirred at room temperature for a further 72 h. Water
(6 mL) was then added, followed by 0.5 h of stirring, after which
the mixture was cooled to 0 &#x000b0;C. The resulting precipitate was
collected by vacuum filtration and washed with water (4 &#x000d7; 20
mL). Purification by flash column chromatography (MeOH/EtOAc, 1:19)
gave <bold>21</bold> (19.0 mg, 34%) as a white foam; IR (neat): 3200,
2924, 1630, 1429, 1256, 1005, 750, 731 cm<sup>&#x02013;1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, &#x003b4;): 3.21&#x02013;3.99
(m, 8H), 4.27 (s, 2H), 4.59 (s, 2H), 7.03 (br s, 1H), 7.30&#x02013;7.36
(m, 2H), 7.37&#x02013;7.49 (m, 4H), 7.67&#x02013;7.72 (m, 1H), 7.73&#x02013;7.80
(m, 2H), 8.44&#x02013;8.49 (m, 1H), 10.84 (br s, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>, &#x003b4;): 37.8 (CH<sub>2</sub>),
42.3 (2 &#x000d7; CH<sub>2</sub>), 45.6 (CH<sub>2</sub>), 47.1 (2 &#x000d7;
CH<sub>2</sub>), 116.3 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 19.9 Hz), 123.8 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 17.7 Hz), 125.1 (CH), 127.4 (CH), 127.7 (2 &#x000d7; CH), 128.5 (C),
129.0 (2 &#x000d7; CH), 129.4 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.6 Hz), 129.7 (C), 131.8 (CH), 132.0 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 8.2 Hz), 132.1 (2 &#x000d7;
CH), 133.8 (CH), 134.6 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.5 Hz), 135.2 (C), 139.7 (C), 145.6 (C), 157.2 (C, d, <italic>J</italic><sub>C&#x02013;F</sub> = 248.1 Hz), 160.5 (C), 165.3 (C),
170.2 (C); HRMS (ESI): [MNa<sup>+</sup>] calcd for C<sub>28</sub>H<sub>24</sub><sup>35</sup>ClFN<sub>4</sub>NaO<sub>3</sub>, 541.1413; found,
541.1413.</p></sec><sec id="sec4.13"><title>4-[3&#x02032;-[4&#x02033;-(4&#x02034;-Chloromethyl)benzoyl)piperazine-1&#x02033;-carbonyl]-4&#x02032;-fluorobenzyl]-2<italic>-tert-</italic>butyloxycarbonylphthalazin-1-one (<bold>22</bold>)</title><p>To a solution of <bold>21</bold> (170 mg, 0.328 mmol) in MeCN (1.5
mL) was added di-<italic>tert</italic>-butyl dicarbonate (86.0 mg,
0.393 mmol) and DMAP (4.00 mg, 0.0328 mmol). The mixture was stirred
at room temperature for 4 h followed by the evaporation of solvent
in vacuo. The crude product was extracted into EtOAc (5 mL), and the
organic layer was washed with water (3 &#x000d7; 10 mL), dried with MgSO<sub>4</sub>, filtered and concentrated in vacuo to give 22 as a white
foam (148 mg, 72%); IR (neat): 2982, 1634, 1427, 1248, 1003, 750 cm<sup>&#x02013;1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, &#x003b4;):
1.66 (s, 9H), 3.15&#x02013;3.99 (m, 8H), 4.30 (s, 2H), 4.59 (s, 2H),
7.03 (br s, 1H), 7.30&#x02013;7.36 (m, 2H), 7.37&#x02013;7.49 (m, 4H),
7.59&#x02013;7.67 (m, 1H), 7.69&#x02013;7.78 (m, 2H), 8.42&#x02013;8.49
(m, 1H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>, &#x003b4;):
27.8 (3 &#x000d7; CH<sub>3</sub>), 38.1 (CH<sub>2</sub>), 42.2 (2 &#x000d7;
CH<sub>2</sub>), 45.4 (CH<sub>2</sub>), 47.1 (2 &#x000d7; CH<sub>2</sub>), 85.9 (C), 116.2 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 20.4 Hz), 123.7 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;F</sub> = 18.2 Hz), 125.1 (CH), 127.6 (2 &#x000d7; CH), 128.1 (CH), 128.7 (C),
128.8 (2 &#x000d7; CH), 129.1 (C), 129.2 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.4 Hz), 131.8 (CH, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;F</sub> = 7.6 Hz), 132.0
(CH), 134.0 (CH), 134.1 (C, d, <italic>J</italic><sub>C&#x02013;C&#x02013;C&#x02013;C&#x02013;F</sub> = 3.7 Hz), 135.1 (C), 139.5 (C), 145.3 (C), 151.1 (C), 157.0 (C,
d, <italic>J</italic><sub>C&#x02013;F</sub> = 247.7 Hz), 158.2 (C),
165.1 (C), 170.0 (C); HRMS (ESI): [MNa<sup>+</sup>] calcd for C<sub>33</sub>H<sub>32</sub><sup>35</sup>ClFN<sub>4</sub>NaO<sub>5</sub>, 641.1937; found, 641.1915.</p></sec><sec id="sec4.14"><title>In Vitro Characterization</title><p>Lipophilicity (log <italic>P</italic><sub>oct</sub>) and percentage
plasma protein binding values
and the cell-free IC<sub>50</sub> parameter for compounds <bold>8</bold>&#x02013;<bold>13</bold> and <bold>20</bold> were obtained using previously
described HPLC and colorimetric dose&#x02013;response methodologies,
respectively.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Similarly, the cellular
IC<sub>50</sub> parameter of <bold>8</bold> and <bold>20</bold> and
the plasma stability and intrinsic clearance parameters of compound <bold>20</bold> were established using previously reported methods.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Correlation of cellular fluorescence IC<sub>50</sub> data with cell-free colorimetric IC<sub>50</sub> data was
used to eliminate potential fluorescence assay interference mechanisms.</p></sec><sec id="sec4.15"><title>Generation of <sup>18</sup>F<sup>&#x02013;</sup>/H<sub>2</sub><sup>18</sup>O</title><p>[<sup>18</sup>F]fluoride was generated via
the [<sup>18</sup>O(<italic>p</italic>, <italic>n</italic>)<sup>18</sup>F] nuclear reaction by irradiating [<sup>18</sup>O]water using a
16.5 MeV proton beam (40 &#x003bc;A) produced by a PETtrace 6 cyclotron
unit.</p></sec><sec id="sec4.16"><title>Manual Radiosynthesis of [<sup>18</sup>F]<bold>8</bold></title><p>A stock solution of K<sub>222</sub>/K<sub>2</sub>CO<sub>3</sub> (0.25
mL), prepared by dissolving 100.0 mg of K<sub>222</sub> (0.266 mmol)
in 2 mL of MeCN and adding 12.0 mg of K<sub>2</sub>CO<sub>3</sub> (0.087
mmol) in 0.5 mL of distilled water, was added to a 2 mL v-vial containing
approximately 100 MBq of <sup>18</sup>F<sup>&#x02013;</sup>/H<sub>2</sub><sup>18</sup>O (0.25 mL). The [<sup>18</sup>F]fluoride was dried
by passing a constant stream of argon over the solution at 100 &#x000b0;C
for approximately 20 min; anhydrous MeCN was added in three aliquots
of 0.50 mL to facilitate azeotropic drying. A solution of <bold>14</bold> (1.0&#x02013;5.0 mg, 0.0019&#x02013;0.0095 mmol) in anhydrous <italic>N</italic>-methyl-2-pyrrolidone (0.3 mL) was then added to the v-vial,
and the reaction was allowed to proceed for 30 min at 180 &#x000b0;C.</p></sec><sec id="sec4.17"><title>Manual Radiosynthesis of [<sup>18</sup>F]<bold>20</bold></title><p>A stock solution of 0.750 M TBAHCO<sub>3</sub> was prepared by diluting
2.5 mL of 1.5 M TBAOH with 2.5 mL of distilled water; CO<sub>2</sub> was bubbled through the solution for 2 h until pH 7.7 was reached,
followed by the removal of excess CO<sub>2</sub> by bubbling argon
through the mixture until pH 9.0 was reached. The 0.750 M TBAHCO<sub>3</sub> solution (10 &#x003bc;L) was added to a 2 mL v-vial containing
469&#x02013;572 MBq of <sup>18</sup>F<sup>&#x02013;</sup>/H<sub>2</sub><sup>18</sup>O (0.16 mL). The mixture was vortexed, and the[<sup>18</sup>F]fluoride was dried by passing a constant stream of argon
over the solution at 100 &#x000b0;C for approximately 20 min; anhydrous
MeCN was added in three aliquots of 0.50 mL to facilitate azeotropic
drying. A solution of <bold>22</bold> (4.9 mg, 0.0079 mmol) in anhydrous
MeCN (0.1 mL) and <italic>t</italic>BuOH (0.2 mL) was then added to
the v-vial, and the reaction was allowed to proceed for 30 min at
110 &#x000b0;C. After this, distilled water was added (0.45 mL), and
the reaction was heated at 120 &#x000b0;C for a further 5 min. Next,
the crude reaction mixture was cooled to room temperature, purified
using HPLC, and concentrated in vacuo in an evaporator flask. The
flask was rinsed with MeCN (3 &#x000d7; 0.3 mL) to extract the radiolabeled
compound, and the solution was transferred to a 2 mL v-vial; the solvent
was removed by passing a constant stream of argon over the solution
at 100 &#x000b0;C for approximately 15 min. The radiotracer was reconstituted
in up to 0.65 mL of 5% v/v DMSO in 0.9% w/v saline. The total radiosynthetic
time was 138 &#x000b1; 16 min (<italic>n</italic> = 6).</p></sec><sec id="sec4.18"><title>HPLC Analysis
and Purification of Radiotracers</title><p>All
radiochemical yields were determined by analytical radio-HPLC of the
crude product. Radioactivity yield was determined using the measured
radioactivity of the isolated product. Analytical and preparatory
Dionex UltiMate 300 series HPLC systems with Phenomenex Synergi 4
&#x003bc;m Hydro-RP 80 &#x000c5; 150 mm &#x000d7; 4.60 mm and 150 mm &#x000d7;
10 mm columns, respectively, were used. Column temperatures were set
to 25 &#x000b0;C, and mobile-phase flow rates were 1 and 3 mL/min for
the analytical and preparatory systems, respectively. Analytical UV
detection was performed using a UltiMate diode array detector (190&#x02013;800
nm), and radiodetection was achieved using a Berthold Technologies
Flow Star LB513 detector. Preparatory UV detection was performed using
a Knauer Advanced Scientific Instruments Smartline UV Detector 2500,
and radiodetection was achieved using a pin-diode connected to a Lab
Logic Flow-Count radiodetector. Analysis of [<sup>18</sup>F]<bold>8</bold>, [<sup>18</sup>F]<bold>20</bold>, and [<sup>18</sup>F]<bold>23</bold> were performed on crude reaction mixtures that were cooled
to room temperature. [<sup>18</sup>F]<bold>8</bold> was analyzed using
the following mobile-phase conditions: 0.0&#x02013;20.0 min, 30:70
A/B to 55:45 A/B; 20.0&#x02013;20.5 min, 55/45 A:B to 5:95 A/B; and
20.5&#x02013;25.0 min, 5:95 A/B, where A is MeCN and B is distilled
water. [<sup>18</sup>F]<bold>20</bold> and [<sup>18</sup>F]<bold>23</bold> was analyzed using the following mobile-phase conditions: 0.0&#x02013;15.0
min, 30:70 A/B to 90:10; 15.0&#x02013;20.0 min, 90:10 A/B; 20.0&#x02013;20.5
min, 90:10 to 30:70 A/B; and 20.5&#x02013;25.0 min, 30:70 A/B, where
A is MeCN and B is distilled water. Purification of [<sup>18</sup>F]<bold>20</bold> was performed using the following mobile-phase
conditions: 0.0&#x02013;3.0 min, 30:70 A/B; 3.0&#x02013;30.0 min, 30:70
to 75:25 A/B; 30.0&#x02013;30.1 min, 75:25 to 95:5 A/B; and 30.1&#x02013;35.0
min, 95:5 A/B, where A is MeCN and B is distilled water; the radiolabeled
product was collected at approximately 13.5 min. To confirm the identity
of the radiolabeled products, the retention times of [<sup>18</sup>F]<bold>8</bold>, [<sup>18</sup>F]<bold>20</bold>, and [<sup>18</sup>F]<bold>23</bold> were compared with the retention times obtained
for nonradioactive <bold>8</bold>, <bold>20</bold>, and <bold>23</bold> using the same chromatographic conditions. Because the amount of
[<sup>18</sup>F]<bold>20</bold> that was produced fell below the sensitivity
threshold of the UV detector (&#x0003c;1.68 &#x000d7; 10<sup>&#x02013;4</sup>&#x003bc;mol), molar activity (Ci/&#x003bc;mol) was calculated using
the lowest detectable amount of nonlabeled <bold>20</bold> established
from a calibration plot of a range of concentrations (0.001&#x02013;1.000
mg/mL). All HPLC data acquisition and analyses were carried out using
the Chromeleon 6.8 Chromatography software.</p></sec><sec id="sec4.19"><title>Mouse Glioblastoma Model</title><p>U87MG-Luc2 glioblastoma cell
culture and implantation procedures were performed as reported previously.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Briefly, U87MG-Luc2 cells were purchased commercially
from ATCC and cultured in minimum essential media that has been supplemented
with 10% w/v fetal calf serum and 2 mM <sc>l</sc>-glutamine at 37
&#x000b0;C and 5% v/v CO<sub>2</sub>. Unconscious female CD1 nude mice
(6&#x02013;11 week old; purchased from Charles River Laboratories)
had 5 &#x000d7; 10<sup>6</sup> U87MG-Luc2 cells injected subcutaneously
into the right flank. The resulting tumor xenografts were measured
and monitored visually every 3 days, and tumor-bearing animals were
used for in vivo studies 28&#x02013;30 days post-implantation.</p></sec><sec id="sec4.20"><title>Ex Vivo
Biodistribution with and without Preblockade</title><p>Subcutaneous
tumor bearing mice were administered 1.8&#x02013;2.6
MBq of [<sup>18</sup>F]<bold>20</bold> in 0.11&#x02013;0.21 mL of 5%
v/v DMSO in 0.9% saline via bolus tail-vein injections. The remainder
of the experiment was conducted as described previously.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup></p></sec><sec id="sec4.21"><title>PET&#x02013;MR Imaging</title><p>A single subcutaneous
U87MG-Luc2
tumor bearing female CD1 nude mouse was anaesthetized using inhaled
isoflurane (in medical air; induction 5% v/v; maintenance 2.0&#x02013;2.5%
v/v) and placed in the nanoScan PET&#x02013;MRI scanner (Mediso Medical
Imaging Systems). The mouse received a bolus tail-vein injection of
2.2 MBq of [<sup>18</sup>F]<bold>20</bold> in 5% v/v DMSO in 0.9%
saline, and a 45 min dynamic PET scan (continuous list mode) was initiated
immediately after. This was followed by a whole-body 1T GRE 3D Cor/Sag
MRI scan. The dynamic PET data were corrected for random coincidences,
dead time, scatter, and decay and subsequently reconstructed using
3D Tera-Tomo (Mediso). The reconstructed PET data were automatically
co-registered with the MRI data, and they were subsequently analyzed
using the PMOD 3.504 software. The PET frames from the last 15 min
of the scan were summed to allow for better visual representation
of radiotracer biodistribution. Standardized uptake values (SUV) were
determined by dividing the image radiotracer concentration by the
injected dose divided by the animal weight.</p></sec><sec id="sec4.22"><title>Immunohistochemistry</title><p>Tumor and muscle tissue was prepared
and stained using anti-PARP-1 antibody (mouse antihuman and mouse
antibody; sc-8007; Santa Cruz), as reported previously.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> Haematoxylin and eosin and Ki67 staining were
performed using a Leica ST5020 multi-stainer. Histology images were
acquired using a Zeiss AX10 brightfield microscope at a 5&#x000d7; magnification.</p></sec></sec></body><back><notes id="notes-1" notes-type="si"><title>Supporting Information Available</title><p>The
Supporting Information
is available free of charge on the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org">ACS Publications website</ext-link> at DOI: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.8b00138">10.1021/acs.jmedchem.8b00138</ext-link>.<list id="silist" list-type="simple"><list-item><p>Molecular formula
strings for compounds presented in
the manuscript. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b00138/suppl_file/jm8b00138_si_001.csv">CSV</ext-link>)</p></list-item><list-item><p><sup>1</sup>H and <sup>13</sup>C NMR spectra for all
new compounds, cell-free and cellular IC<sub>50</sub> curves, metabolic
stability graphs, radiofluorination optimization, optimization of
deprotection chemistry, immunohistochemical staining of the U87MG-Luc2
subcutaneous xenograft, radiochemistry HPLC chromatograms, and purity
assessment HPLC chromatograms for key compounds. (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.8b00138/suppl_file/jm8b00138_si_002.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm8b00138_si_001.csv"><caption><p>jm8b00138_si_001.csv</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="sifile2"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jm8b00138_si_002.pdf"><caption><p>jm8b00138_si_002.pdf</p></caption></media></supplementary-material></sec><notes notes-type="COI-statement" id="NOTES-d7e3632-autogenerated"><p>The authors declare the
following competing financial interest(s): Partial funding received
from AstraZeneca, who are patent holders for the PARP inhibitor olaparib.</p></notes><ack><title>Acknowledgments</title><p>The authors
acknowledge Dr. Shafiq Ahmed for providing guidance
concerning the cellular IC<sub>50</sub> assays and Dr. Lesley Gilmour
and Sandeep Chahal for their input in setting up the necessary small-animal
xenograft models. The authors also gratefully acknowledge financial
support from the University of Glasgow (studentship FZ), EPSRC (EP/J500434),
the Cancer Research U.K. Glasgow Centre Development Fund, The Neuroscience
Foundation, The Beatson Cancer Charity, AstraZeneca, and the Scottish
Imaging Network: A Platform for Scientific Excellence.</p></ack><glossary id="dl1"><def-list><title>Abbreviations Used</title><def-item><term>ATCC</term><def><p>American type culture collection</p></def></def-item><def-item><term>BBB</term><def><p>blood&#x02013;brain
barrier</p></def></def-item><def-item><term>BRCA</term><def><p>breast
cancer</p></def></def-item><def-item><term>Cl<sub>int</sub></term><def><p>intrinsic clearance</p></def></def-item><def-item><term>IC<sub>50</sub></term><def><p>half-maximum inhibitory concentration</p></def></def-item><def-item><term>ID/g</term><def><p>injected dose per gram
of material</p></def></def-item><def-item><term>K<sub>222</sub></term><def><p>Kryptofix</p></def></def-item><def-item><term>log <italic>P</italic><sub>oct</sub></term><def><p>lipophilicity</p></def></def-item><def-item><term>MBq</term><def><p>megabequerel</p></def></def-item><def-item><term>MR</term><def><p>magnetic resonance</p></def></def-item><def-item><term>MRI</term><def><p>magnetic resonance imaging</p></def></def-item><def-item><term>PARP</term><def><p>poly(ADP-ribose)
polymerase</p></def></def-item><def-item><term>PARP-1</term><def><p>poly(ADP-ribose) polymerase-1</p></def></def-item><def-item><term>PPB</term><def><p>plasma-protein binding</p></def></def-item><def-item><term>PTA</term><def><p>phase-transfer agent</p></def></def-item><def-item><term>SD</term><def><p>standard deviation</p></def></def-item><def-item><term>SUV</term><def><p>standardized uptake value</p></def></def-item><def-item><term><italic>t-</italic>BuOH</term><def><p><italic>tert</italic>-butyl alcohol</p></def></def-item><def-item><term>TBAF</term><def><p>tetra-<italic>n</italic>-butylammoniumfluorine</p></def></def-item><def-item><term>TBAHCO<sub>3</sub></term><def><p>tetra-<italic>n-</italic>butylammonium hydrogen carbonate</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Am&#x000e9;</surname><given-names>J.</given-names></name>; <name><surname>Spenlehauer</surname><given-names>C.</given-names></name>; <name><surname>de Murcia</surname><given-names>G.</given-names></name>
<article-title>The PARP superfamily</article-title>. <source>BioEssays</source>
<year>2004</year>, <volume>26</volume>, <fpage>882</fpage>&#x02013;<lpage>893</lpage>. <pub-id pub-id-type="doi">10.1002/bies.20085</pub-id>.<pub-id pub-id-type="pmid">15273990</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>B&#x000fc;rkle</surname><given-names>A.</given-names></name>
<article-title>Poly(ADP-ribose)
the most elaborate metabolite of NAD<sup>+</sup></article-title>. <source>FEBS J.</source>
<year>2005</year>, <volume>272</volume>, <fpage>4576</fpage>&#x02013;<lpage>4589</lpage>. <pub-id pub-id-type="doi">10.1111/j.1742-4658.2005.04864.x</pub-id>.<pub-id pub-id-type="pmid">16156780</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="weblink" id="cit3"><collab>U.S. Food and
Drug Administration</collab>. <source>Orange Book:
Approved Drug Products with Therapeutic Equivalence Evaluations</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm">https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm</uri> (accessed
Mar 8, 2018).</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="weblink" id="cit4"><collab>European Medicines Agency</collab>. <source>European public assessment
reports</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&#x00026;mid=WC0b01ac058001d124">http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&#x00026;mid=WC0b01ac058001d124</uri> (accessed Mar 8, 2018).</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Ledermann</surname><given-names>J.
A.</given-names></name>; <name><surname>Harter</surname><given-names>P.</given-names></name>; <name><surname>Gourley</surname><given-names>C.</given-names></name>; <name><surname>Friedlander</surname><given-names>M.</given-names></name>; <name><surname>Vergote</surname><given-names>I.</given-names></name>; <name><surname>Rustin</surname><given-names>G.</given-names></name>; <name><surname>Scott</surname><given-names>C. L.</given-names></name>; <name><surname>Meier</surname><given-names>W.</given-names></name>; <name><surname>Shapira-Frommer</surname><given-names>R.</given-names></name>; <name><surname>Safra</surname><given-names>T.</given-names></name>; <name><surname>Matei</surname><given-names>D.</given-names></name>; <name><surname>Fielding</surname><given-names>A.</given-names></name>; <name><surname>Spencer</surname><given-names>S.</given-names></name>; <name><surname>Dougherty</surname><given-names>B.</given-names></name>; <name><surname>Orr</surname><given-names>M.</given-names></name>; <name><surname>Hodgson</surname><given-names>D.</given-names></name>; <name><surname>Barrett</surname><given-names>J. C.</given-names></name>; <name><surname>Matulonis</surname><given-names>U.</given-names></name>
<article-title>Olaparib maintenance therapy in patients
with platinum-sensitive relapsed serous ovarian cancer: a preplanned
retrospective analysis of outcomes by BRCA status in a randomised
phase 2 trial</article-title>. <source>Lancet Oncol.</source>
<year>2014</year>, <volume>15</volume>, <fpage>852</fpage>&#x02013;<lpage>861</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(14)70228-1</pub-id>.<pub-id pub-id-type="pmid">24882434</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Ledermann</surname><given-names>J. A.</given-names></name>; <name><surname>Harter</surname><given-names>H.</given-names></name>; <name><surname>Gourley</surname><given-names>C.</given-names></name>; <name><surname>Friedlander</surname><given-names>M.</given-names></name>; <name><surname>Vergote</surname><given-names>I.</given-names></name>; <name><surname>Rustin</surname><given-names>G.</given-names></name>; <name><surname>Scott</surname><given-names>C.</given-names></name>; <name><surname>Meier</surname><given-names>W.</given-names></name>; <name><surname>Shapira-Frommer</surname><given-names>R.</given-names></name>; <name><surname>Safra</surname><given-names>T.</given-names></name>; <name><surname>Matei</surname><given-names>D.</given-names></name>; <name><surname>Fielding</surname><given-names>A.</given-names></name>; <name><surname>Spencer</surname><given-names>S.</given-names></name>; <name><surname>Rowe</surname><given-names>P.</given-names></name>; <name><surname>Lowe</surname><given-names>E.</given-names></name>; <name><surname>Hodgson</surname><given-names>D.</given-names></name>; <name><surname>Sovak</surname><given-names>M. A.</given-names></name>; <name><surname>Matulonis</surname><given-names>U.</given-names></name>
<article-title>Overall survival
in patients with
platinum-sensitive recurrent serous ovarian cancer receiving olaparib
maintenance monotherapy: an updated analysis from a randomised, placebo-controlled,
double-blind, phase 2 trial</article-title>. <source>Lancet Oncol.</source>
<year>2016</year>, <volume>17</volume>, <fpage>1579</fpage>&#x02013;<lpage>1589</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(16)30376-X</pub-id>.<pub-id pub-id-type="pmid">27617661</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="weblink" id="cit7"><collab>U.S. Food and Drug Administration</collab>. <source>FDA approves
olaparib for germline BRCA-mutated metastatic breast cancer</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm592357.htm">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm592357.htm</uri> (accessed Mar 24, 2018).</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="weblink" id="cit8"><collab>U.S. Food and Drug Administration</collab>. <source>FDA approves
olaparib tablets for maintenance treatment in ovarian cancer</source>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm572143.htm">https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm572143.htm</uri> (accessed March 24, 2018).</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Ledermann</surname><given-names>J.
A.</given-names></name>; <name><surname>Harter</surname><given-names>P.</given-names></name>; <name><surname>Gourley</surname><given-names>C.</given-names></name>; <name><surname>Friedlander</surname><given-names>M.</given-names></name>; <name><surname>Vergote</surname><given-names>I.</given-names></name>; <name><surname>Rustin</surname><given-names>G.</given-names></name>; <name><surname>Scott</surname><given-names>C.</given-names></name>; <name><surname>Meier</surname><given-names>W.</given-names></name>; <name><surname>Shapira-Frommer</surname><given-names>R.</given-names></name>; <name><surname>Safra</surname><given-names>T.</given-names></name>; <name><surname>Matei</surname><given-names>D.</given-names></name>; <name><surname>Macpherson</surname><given-names>E.</given-names></name>; <name><surname>Watkins</surname><given-names>C.</given-names></name>; <name><surname>Carmichael</surname><given-names>J.</given-names></name>; <name><surname>Matulonis</surname><given-names>U.</given-names></name>
<article-title>Olaparib maintenance
therapy in platinum-sensitive relapsed ovarian cancer</article-title>. <source>N. Engl. J. Med.</source>
<year>2012</year>, <volume>366</volume>, <fpage>1382</fpage>&#x02013;<lpage>1392</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1105535</pub-id>.<pub-id pub-id-type="pmid">22452356</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Robson</surname><given-names>M.</given-names></name>; <name><surname>Im</surname><given-names>S. A.</given-names></name>; <name><surname>Senkus</surname><given-names>E.</given-names></name>; <name><surname>Xu</surname><given-names>B.</given-names></name>; <name><surname>Domchek</surname><given-names>S. M.</given-names></name>; <name><surname>Masuda</surname><given-names>N.</given-names></name>; <name><surname>Delaloge</surname><given-names>S.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Tung</surname><given-names>N.</given-names></name>; <name><surname>Armstrong</surname><given-names>A.</given-names></name>; <name><surname>Wu</surname><given-names>W.</given-names></name>; <name><surname>Goessl</surname><given-names>C.</given-names></name>; <name><surname>Runswick</surname><given-names>S.</given-names></name>; <name><surname>Conte</surname><given-names>P.</given-names></name>
<article-title>Olaparib for metastatic breast cancer in patients with a germline
BRCA mutation</article-title>. <source>N. Engl. J. Med.</source>
<year>2017</year>, <volume>377</volume>, <fpage>523</fpage>&#x02013;<lpage>533</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1706450</pub-id>.<pub-id pub-id-type="pmid">28578601</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Evans</surname><given-names>T.</given-names></name>; <name><surname>Matulonis</surname><given-names>U.</given-names></name>
<article-title>PARP inhibitors
in ovarian cancer: evidence, experience
and clinical potential</article-title>. <source>Ther. Adv. Med. Oncol.</source>
<year>2017</year>, <volume>9</volume>, <fpage>253</fpage>&#x02013;<lpage>267</lpage>. <pub-id pub-id-type="doi">10.1177/1758834016687254</pub-id>.<pub-id pub-id-type="pmid">28491146</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Chalmers</surname><given-names>A.</given-names></name>; <name><surname>Jackson</surname><given-names>A.</given-names></name>; <name><surname>Swaisland</surname><given-names>H.</given-names></name>; <name><surname>Stewart</surname><given-names>W.</given-names></name>; <name><surname>Halford</surname><given-names>S. E. R.</given-names></name>; <name><surname>Molife</surname><given-names>L. R.</given-names></name>; <name><surname>Hargrave</surname><given-names>D.</given-names></name>; <name><surname>McCormick</surname><given-names>A.</given-names></name>
<article-title>Results of
stage 1 of the operatic trial: a phase I study of olaparib in combination
with Temozolomide in patients with relapsed glioblastoma [abstract]</article-title>. <source>J. Clin. Oncol.</source>
<year>2014</year>, <volume>32</volume>, <fpage>2025</fpage><pub-id pub-id-type="doi">10.1200/jco.2014.32.15_suppl.2025</pub-id>.<pub-id pub-id-type="pmid">24888800</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Roelcke</surname><given-names>U.</given-names></name>; <name><surname>Rad&#x000fc;</surname><given-names>E. W.</given-names></name>; <name><surname>von Ammon</surname><given-names>K.</given-names></name>; <name><surname>Hausmann</surname><given-names>O.</given-names></name>; <name><surname>Maguire</surname><given-names>R. P.</given-names></name>; <name><surname>Leenders</surname><given-names>K. L.</given-names></name>
<article-title>Alteration of blood-brain barrier in human brain tumors:
comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82
using PET</article-title>. <source>J. Neurol. Sci.</source>
<year>1995</year>, <volume>132</volume>, <fpage>20</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/0022-510X(95)00117-K</pub-id>.<pub-id pub-id-type="pmid">8523026</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Kracht</surname><given-names>L. W.</given-names></name>; <name><surname>Miletic</surname><given-names>H.</given-names></name>; <name><surname>Busch</surname><given-names>S.</given-names></name>; <name><surname>Jacobs</surname><given-names>A. H.</given-names></name>; <name><surname>Voges</surname><given-names>J.</given-names></name>; <name><surname>Hoevels</surname><given-names>M.</given-names></name>; <name><surname>Klein</surname><given-names>J. C.</given-names></name>; <name><surname>Herholz</surname><given-names>K.</given-names></name>; <name><surname>Heiss</surname><given-names>W. D.</given-names></name>
<article-title>Delineation
of brain tumour extent with [11C]L-methionine positron emission tomography:
local comparison with stereotactic histopathology</article-title>. <source>Clin. Cancer Res.</source>
<year>2004</year>, <volume>10</volume>, <fpage>7163</fpage>&#x02013;<lpage>7170</lpage>.<pub-id pub-id-type="pmid">15534088</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Wolburg</surname><given-names>H.</given-names></name>; <name><surname>Noell</surname><given-names>S.</given-names></name>; <name><surname>Fallier-Becker</surname><given-names>P.</given-names></name>; <name><surname>Mack</surname><given-names>A.</given-names></name>; <name><surname>Wolburg-Buchholz</surname><given-names>K.</given-names></name>
<article-title>The disrupted
blood-brain barrier in human glioblastoma</article-title>. <source>Mol.
Aspects Med.</source>
<year>2012</year>, <volume>33</volume>, <fpage>579</fpage>&#x02013;<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1016/j.mam.2012.02.003</pub-id>.<pub-id pub-id-type="pmid">22387049</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Rottenberg</surname><given-names>S.</given-names></name>; <name><surname>Jaspers</surname><given-names>J. E.</given-names></name>; <name><surname>Kersbergen</surname><given-names>A.</given-names></name>; <name><surname>van der Burg</surname><given-names>E.</given-names></name>; <name><surname>Nygren</surname><given-names>A. O.</given-names></name>; <name><surname>Zander</surname><given-names>S. A.</given-names></name>; <name><surname>Derksen</surname><given-names>P. W.</given-names></name>; <name><surname>de Bruin</surname><given-names>M.</given-names></name>; <name><surname>Zevenhoven</surname><given-names>J.</given-names></name>; <name><surname>Boulter</surname><given-names>R.</given-names></name>; <name><surname>Cranston</surname><given-names>A.</given-names></name>; <name><surname>O&#x02019;Connor</surname><given-names>M. J.</given-names></name>; <name><surname>Martin</surname><given-names>N. M.</given-names></name>; <name><surname>Borst</surname><given-names>P.</given-names></name>; <name><surname>Jonkers</surname><given-names>J.</given-names></name>; <name><surname>Lau</surname><given-names>A.</given-names></name>
<article-title>High sensitivity
of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone
and in combination with platinum drugs</article-title>. <source>Proc.
Natl. Acad. Sci. U. S. A.</source>
<year>2008</year>, <volume>105</volume>, <fpage>17079</fpage>&#x02013;<lpage>17084</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0806092105</pub-id>.<pub-id pub-id-type="pmid">18971340</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Carney</surname><given-names>B.</given-names></name>; <name><surname>Kossatz</surname><given-names>S.</given-names></name>; <name><surname>Lok</surname><given-names>B. H.</given-names></name>; <name><surname>Schneeberger</surname><given-names>V.</given-names></name>; <name><surname>Gangangari</surname><given-names>K. K.</given-names></name>; <name><surname>Pillarsetty</surname><given-names>N. V. K.</given-names></name>; <name><surname>Weber</surname><given-names>W. A.</given-names></name>; <name><surname>Rudin</surname><given-names>C. M.</given-names></name>; <name><surname>Poirier</surname><given-names>J. T.</given-names></name>; <name><surname>Reiner</surname><given-names>T.</given-names></name>
<article-title>Target engagement imaging of PARP
inhibitors in small-cell lung cancer</article-title>. <source>Nat. Commun.</source>
<year>2018</year>, <volume>9</volume>, <fpage>176</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-02096-w</pub-id>.<pub-id pub-id-type="pmid">29330466</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Makvandi</surname><given-names>M.</given-names></name>; <name><surname>Pantel</surname><given-names>A.</given-names></name>; <name><surname>Schwartz</surname><given-names>L.</given-names></name>; <name><surname>Schubert</surname><given-names>E.</given-names></name>; <name><surname>Xu</surname><given-names>K.</given-names></name>; <name><surname>Hsieh</surname><given-names>C.</given-names></name>; <name><surname>Hou</surname><given-names>C.</given-names></name>; <name><surname>Kim</surname><given-names>H.</given-names></name>; <name><surname>Weng</surname><given-names>C.</given-names></name>; <name><surname>Winters</surname><given-names>H.</given-names></name>; <name><surname>Doot</surname><given-names>R.</given-names></name>; <name><surname>Farwell</surname><given-names>M. D.</given-names></name>; <name><surname>Pryma</surname><given-names>D. A.</given-names></name>; <name><surname>Greenberg</surname><given-names>R. A.</given-names></name>; <name><surname>Mankoff</surname><given-names>D. A.</given-names></name>; <name><surname>Simpkins</surname><given-names>F.</given-names></name>; <name><surname>Mach</surname><given-names>R. H.</given-names></name>; <name><surname>Lin</surname><given-names>L. L.</given-names></name>
<article-title>A PET imaging agent for evaluating
PARP-1 expression
in ovarian cancer</article-title>. <source>J. Clin. Invest.</source>
<year>2018</year>, <fpage>1</fpage><pub-id pub-id-type="doi">10.1172/JCI97992</pub-id>.<pub-id pub-id-type="pmid">29293098</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Zmuda</surname><given-names>F.</given-names></name>; <name><surname>Malviya</surname><given-names>G.</given-names></name>; <name><surname>Blair</surname><given-names>A.</given-names></name>; <name><surname>Boyd</surname><given-names>M.</given-names></name>; <name><surname>Chalmers</surname><given-names>A.</given-names></name>; <name><surname>Sutherland</surname><given-names>A.</given-names></name>; <name><surname>Pimlott</surname><given-names>S. L.</given-names></name>
<article-title>Synthesis and evaluation of a radioiodinated
tracer with specificity for poly(ADP-ribose) polymerase-1 (PARP-1)
in vivo</article-title>. <source>J. Med. Chem.</source>
<year>2015</year>, <volume>58</volume>, <fpage>8683</fpage>&#x02013;<lpage>8693</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01324</pub-id>.<pub-id pub-id-type="pmid">26469301</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Khalil</surname><given-names>M.</given-names></name>; <name><surname>Tremoleda</surname><given-names>J.</given-names></name>; <name><surname>Bayomy</surname><given-names>T.</given-names></name>; <name><surname>Gsell</surname><given-names>W.</given-names></name>
<article-title>Molecular SPECT imaging:
an overview</article-title>. <source>Int. J. Mol. Imaging</source>
<year>2011</year>, <volume>2011</volume>, <fpage>796025</fpage><pub-id pub-id-type="doi">10.1155/2011/796025</pub-id>.<pub-id pub-id-type="pmid">21603240</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Rahmim</surname><given-names>A.</given-names></name>; <name><surname>Zaidi</surname><given-names>H.</given-names></name>
<article-title>PET versus SPECT: strengths,
limitations and challenges</article-title>. <source>Nucl. Med. Commun.</source>
<year>2008</year>, <volume>29</volume>, <fpage>193</fpage>&#x02013;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1097/MNM.0b013e3282f3a515</pub-id>.<pub-id pub-id-type="pmid">18349789</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Carney</surname><given-names>B.</given-names></name>; <name><surname>Kossatz</surname><given-names>S.</given-names></name>; <name><surname>Reiner</surname><given-names>T.</given-names></name>
<article-title>Molecular
imaging of PARP</article-title>. <source>J. Nucl. Med.</source>
<year>2017</year>, <volume>58</volume>, <fpage>1025</fpage>&#x02013;<lpage>1030</lpage>. <pub-id pub-id-type="doi">10.2967/jnumed.117.189936</pub-id>.<pub-id pub-id-type="pmid">28473593</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Knight</surname><given-names>J.</given-names></name>; <name><surname>Koustoulidou</surname><given-names>S.</given-names></name>; <name><surname>Cornelissen</surname><given-names>B.</given-names></name>
<article-title>Imaging the DNA damage response with
PET and SPECT</article-title>. <source>Eur. J. Nucl. Med. Mol. Imaging</source>
<year>2017</year>, <volume>44</volume>, <fpage>1065</fpage>&#x02013;<lpage>1078</lpage>. <pub-id pub-id-type="doi">10.1007/s00259-016-3604-1</pub-id>.<pub-id pub-id-type="pmid">28058462</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Pantel</surname><given-names>A.</given-names></name>; <name><surname>MaKvandi</surname><given-names>M.</given-names></name>; <name><surname>Doot</surname><given-names>R.</given-names></name>; <name><surname>Schwartz</surname><given-names>L.</given-names></name>; <name><surname>Greenberg</surname><given-names>R.</given-names></name>; <name><surname>Simpkins</surname><given-names>F.</given-names></name>; <name><surname>Mankoff</surname><given-names>D.</given-names></name>; <name><surname>Lin</surname><given-names>L.l</given-names></name>; <name><surname>Mach</surname><given-names>R.</given-names></name>
<article-title>A pilot study
of a novel poly(ADP-ribose) polymerase-1 (PARP) PET tracer ([<sup>18</sup>F]FluorThanatrace) in patients with ovarian carcinoma</article-title>. <source>J. Nucl. Med.</source>
<year>2017</year>, <volume>58</volume> (<issue>1</issue>), <fpage>386</fpage>.</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Reiner</surname><given-names>T.</given-names></name>; <name><surname>Lacy</surname><given-names>J.</given-names></name>; <name><surname>Keliher</surname><given-names>J.</given-names></name>; <name><surname>Yang</surname><given-names>S.</given-names></name>; <name><surname>Ullal</surname><given-names>A.</given-names></name>; <name><surname>Kohler</surname><given-names>H.</given-names></name>; <name><surname>Vinegoni</surname><given-names>C.</given-names></name>; <name><surname>Weissleder</surname><given-names>R.</given-names></name>
<article-title>Imaging therapeutic
PARP inhibition in vivo through bioorthogonally developed companion
imaging agents</article-title>. <source>Neoplasia</source>
<year>2012</year>, <volume>14</volume>, <fpage>169</fpage>&#x02013;<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1593/neo.12414</pub-id>.<pub-id pub-id-type="pmid">22496617</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Cockcroft</surname><given-names>X. L.</given-names></name>; <name><surname>Dillon</surname><given-names>J.</given-names></name>; <name><surname>Dixon</surname><given-names>L.</given-names></name>; <name><surname>Drzewiecki</surname><given-names>J.</given-names></name>; <name><surname>Kerrigan</surname><given-names>F.</given-names></name>; <name><surname>Loh</surname><given-names>V. M.</given-names></name>; <name><surname>Martin</surname><given-names>N. M.</given-names></name>; <name><surname>Menear</surname><given-names>K. A.</given-names></name>; <name><surname>Smith</surname><given-names>G. C.</given-names></name>
<article-title>Phthalazinones 2: optimization and
synthesis of novel
potent inhibitors of poly(ADP-ribose)polymerase</article-title>. <source>Bioorg. Med. Chem. Lett.</source>
<year>2006</year>, <volume>16</volume>, <fpage>1040</fpage>&#x02013;<lpage>1044</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2005.10.081</pub-id>.<pub-id pub-id-type="pmid">16290932</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Menear</surname><given-names>K. A.</given-names></name>; <name><surname>Adcock</surname><given-names>C.</given-names></name>; <name><surname>Boulter</surname><given-names>R.</given-names></name>; <name><surname>Cockcroft</surname><given-names>X. L.</given-names></name>; <name><surname>Copsey</surname><given-names>L.</given-names></name>; <name><surname>Cranston</surname><given-names>A.</given-names></name>; <name><surname>Dillon</surname><given-names>K. J.</given-names></name>; <name><surname>Drzewiecki</surname><given-names>J.</given-names></name>; <name><surname>Garman</surname><given-names>S.</given-names></name>; <name><surname>Gomez</surname><given-names>S.</given-names></name>; <name><surname>Javaid</surname><given-names>H.</given-names></name>; <name><surname>Kerrigan</surname><given-names>F.</given-names></name>; <name><surname>Knights</surname><given-names>C.</given-names></name>; <name><surname>Lau</surname><given-names>A.</given-names></name>; <name><surname>Loh</surname><given-names>V. M.</given-names></name>; <name><surname>Matthews</surname><given-names>I. T.</given-names></name>; <name><surname>Moore</surname><given-names>S.</given-names></name>; <name><surname>O&#x02019;Connor</surname><given-names>M. J.</given-names></name>; <name><surname>Smith</surname><given-names>G. C.</given-names></name>; <name><surname>Martin</surname><given-names>N. M.</given-names></name>
<article-title>4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]2H-phthalazin-1-one:
a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1</article-title>. <source>J. Med. Chem.</source>
<year>2008</year>, <volume>51</volume>, <fpage>6581</fpage>&#x02013;<lpage>6591</lpage>. <pub-id pub-id-type="doi">10.1021/jm8001263</pub-id>.<pub-id pub-id-type="pmid">18800822</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Helmer</surname><given-names>F.</given-names></name>; <name><surname>Kiehs</surname><given-names>K.</given-names></name>; <name><surname>Hansch</surname><given-names>C.</given-names></name>
<article-title>The linear free-energy relationship
between partition coefficients and the binding and conformational
perturbation of macromolecules by small organic compounds</article-title>. <source>Biochemistry</source>
<year>1968</year>, <volume>7</volume>, <fpage>2858</fpage>&#x02013;<lpage>2863</lpage>. <pub-id pub-id-type="doi">10.1021/bi00848a023</pub-id>.<pub-id pub-id-type="pmid">5666755</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Jacobson</surname><given-names>O.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>
<article-title>Interrogating tumor metabolism and tumor microenvironments using
molecular positron emission tomography imaging. Theranostic approaches
to improve therapeutics</article-title>. <source>Pharmacol. Rev.</source>
<year>2013</year>, <volume>65</volume>, <fpage>1214</fpage>&#x02013;<lpage>1256</lpage>. <pub-id pub-id-type="doi">10.1124/pr.113.007625</pub-id>.<pub-id pub-id-type="pmid">24064460</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Tavares</surname><given-names>A.</given-names></name>; <name><surname>Lewsey</surname><given-names>J.</given-names></name>; <name><surname>Dewar</surname><given-names>D.</given-names></name>; <name><surname>Pimlott</surname><given-names>S.</given-names></name>
<article-title>Radiotracer properties
by high performance liquid chromatography: a potential tool for brain
radiotracer discovery</article-title>. <source>Nucl. Med. Biol.</source>
<year>2012</year>, <volume>39</volume>, <fpage>127</fpage>&#x02013;<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1016/j.nucmedbio.2011.06.011</pub-id>.<pub-id pub-id-type="pmid">21958855</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Lee</surname><given-names>S. J.</given-names></name>; <name><surname>Oh</surname><given-names>S. J.</given-names></name>; <name><surname>Chi</surname><given-names>D. Y.</given-names></name>; <name><surname>Lee</surname><given-names>B. S.</given-names></name>; <name><surname>Ryu</surname><given-names>J. S.</given-names></name>; <name><surname>Moon</surname><given-names>D. H.</given-names></name>
<article-title>Comparison of synthesis
yields of 3&#x02032;-deoxy-3&#x02032;-[18F]fluorothymidine
by nucleophilic fluorination in various alcohol solvents</article-title>. <source>J. Labelled Compd. Radiopharm.</source>
<year>2008</year>, <volume>51</volume>, <fpage>80</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1002/jlcr.1478</pub-id>.</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Kim</surname><given-names>W.</given-names></name>; <name><surname>Jeong</surname><given-names>H.</given-names></name>; <name><surname>Lim</surname><given-names>T.</given-names></name>; <name><surname>Sohn</surname><given-names>M.</given-names></name>; <name><surname>Katzenellenbogen</surname><given-names>A.</given-names></name>; <name><surname>Chi</surname><given-names>Y.</given-names></name>
<article-title>Facile nucleophilic fluorination reactions using tert-alcohols as
a reaction medium: significantly enhanced reactivity of alkali metal
fluorides and improved selectivity</article-title>. <source>J. Org.
Chem.</source>
<year>2008</year>, <volume>73</volume>, <fpage>957</fpage>&#x02013;<lpage>962</lpage>. <pub-id pub-id-type="doi">10.1021/jo7021229</pub-id>.<pub-id pub-id-type="pmid">18166063</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Salinas</surname><given-names>B.</given-names></name>; <name><surname>Irwin</surname><given-names>P.</given-names></name>; <name><surname>Kossatz</surname><given-names>S.</given-names></name>; <name><surname>Bolaender</surname><given-names>A.</given-names></name>; <name><surname>Chiosis</surname><given-names>G.</given-names></name>; <name><surname>Pillarsetty</surname><given-names>N.</given-names></name>; <name><surname>Weber</surname><given-names>W. A.</given-names></name>; <name><surname>Reiner</surname><given-names>T.</given-names></name>
<article-title>Radioiodinated
PARP1 tracers for glioblastoma imaging</article-title>. <source>EJNMMI
Res.</source>
<year>2015</year>, <volume>5</volume>, <fpage>1</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1186/s13550-015-0123-1</pub-id>.<pub-id pub-id-type="pmid">25853007</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Carney</surname><given-names>B.</given-names></name>; <name><surname>Carlucci</surname><given-names>G.</given-names></name>; <name><surname>Salinas</surname><given-names>B.</given-names></name>; <name><surname>Di Gialleonardo</surname><given-names>D.</given-names></name>; <name><surname>Kossatz</surname><given-names>S.</given-names></name>; <name><surname>Vansteene</surname><given-names>A.</given-names></name>; <name><surname>Longo</surname><given-names>V. A.</given-names></name>; <name><surname>Bolaender</surname><given-names>A.</given-names></name>; <name><surname>Chiosis</surname><given-names>G.</given-names></name>; <name><surname>Keshari</surname><given-names>K. R.</given-names></name>; <name><surname>Weber</surname><given-names>W. A.</given-names></name>; <name><surname>Reiner</surname><given-names>T.</given-names></name>
<article-title>Non-invasive
PET imaging of PARP1 expression in glioblastoma models</article-title>. <source>Mol. Imaging Biol.</source>
<year>2016</year>, <volume>18</volume>, <fpage>386</fpage>&#x02013;<lpage>392</lpage>. <pub-id pub-id-type="doi">10.1007/s11307-015-0904-y</pub-id>.<pub-id pub-id-type="pmid">26493053</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Pike</surname><given-names>V. W.</given-names></name>
<article-title>PET radiotracers:
crossing the blood-brain barrier and surviving metabolism</article-title>. <source>Trends Pharmacol. Sci.</source>
<year>2009</year>, <volume>30</volume>, <fpage>431</fpage>&#x02013;<lpage>440</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2009.05.005</pub-id>.<pub-id pub-id-type="pmid">19616318</pub-id></mixed-citation></ref></ref-list></back></article>
